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ABSTRACT 
CYNTHIA DENISE BRADSHAW. Roles of Phospholipase D and 
Sphingomyelinase in T-Cell Signaling. (Under the direction of 
KATHRYN E. MEIER, Ph.D). 
The overall goal of this study was to investigate the roles of 
PLD and neutral SMase in signal transduction in T-Iymphocytes. In 
particular, the abilities of phospholipid metabolites to regulate 
mitogen-activated protein kinases were explored. The tumor-
promoting PKC activator, phorbol 12-myristate 13-acetate (PMA), 
and an antileukemic drug, 1-8-D arabinofuranosylcytosine 
hydrochloride (Ara-C), were used as model phospholipase activators. 
The effects of phorbol ester and Ara-C on PLD and SMase 
activities were examined in EL4, a murine thymoma cell line, and 
Jurkat, a human leukemia cell line. PLD activity was measured in 
intact cells using a metabolic labelling assay. PLD and SMase 
activities were measured In membrane extracts utilizing 
fluorescent phosphatidylcholine (PLD) and sphingomyelin (SMase) as 
x 
substrates, respectively. Rapid activation of PLD by PMA was 
detected in Jurkat cells, but not in EL4 cells. Jurkat, but not EL4 
cells, express a 120-kDa protein recognized by an anti-PLD antibody. 
Ara-C activated neutral SMase within 10 minutes in both Jurkat and 
EL4. PMA did not activate SMase and Ara-C did not activate PLD. 
The relationships between activation of PLD, SMase and 
members of the mitogen-activated protein kinase family, ERKs 
(extracellular-regulated kinases) and JNKs (c-jun N-terminal 
kinases), were examined using in vitro phosphorylation assays. PMA 
induced activation of ERKs in both Jurkat and EL4 cells, while Ara-C 
or ceramides had no effect. Incubation of EL4 cells with bacterial 
PLD increased phosphatidic acid levels, but did not activate ERKs. 
JNK activity was detected within 10 minutes after co-stimulation 
with PMA and ionomycin in both EL4 and Jurkat cells. Ara-C 
activated JNKs in these cells only after prolonged incubation (90-
120 minutes). These results suggest that activation of PLD is 
neither necessary nor sufficient for activation of ERKs or JNKs. The 
delayed effects of Ara-C on JNK activity may be mediated through 
secondary response pathways. 
The mechanism by which PMA activates PLD was examined In 
XI 
Jurkat cells and in a prostate cancer cell line. No evidence was 
obtained for PLD translocation, phosphorylation, or binding to 
protein kinase Ca. These results are consistent with observations 
that PLD can be activated by protein-protein and/or protein-lipid 
interactions. 
The data obtained in these studies indicate that PLD and 
neutral SMase are activated via distinct pathways in T-Iymphocyte 
cell lines. While their reaction products do not directly regulate 
mitogen-activated protein kinases, the activation of these 
phospholipases by mitogenic and cytotoxic stimuli suggest that 
further understanding of the regulation of PLD and SMase and their 
roles in signal transduction may present future avenues for the 
improved therapy of T-Iymphocyte pathologies. 
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CHAPTER 1 
General I ntrod ucti on 
1.1 Phospholipases and Lipid Mediators in Signal 
Transduction 
Lipid mediators play crucial roles in signal transduction. These 
molecules are considered important in cell proliferation, and in 
processes involving cell-cell communication including host defense 
and inflammation (Serhan et al., 1996). The activation of specific 
phospholipases within individual cell types, mediated by 
extracellular signals generated during these multicellular 
processes, IS the initiating step in the biosynthesis of several 
structurally diverse lipid mediators (Billah et al., 1990; Serhan e t 
al., 1996). Phospholipases involved include phospholipase A2 (PLA2), 
phospholipase C (PLC), phospholipase D (PLD), and sphingomyelinase 
(SMase), each of which is pivotal in the biosynthesis of lipid 
mediators (Billah et al., 1990; Serhan et al., 1996). Activation of 
these enzymes is accomplished by a wide range of agonists. The 
lipid mediators produced include free fatty acids, Iysophospholipids, 
platelet activating factor (PAF), diglyceride (DAG), phosphatidic 
acid, ceramide, and oxygenated fatty acid metabolites (Serhan et al., 
1996). These metabolites have been implicated as essential 
mediators in a variety of tissue and" cell functions. Each major 
2 
group of phospholipase (Figure 1-1) contains multiple family 
members that carry out similar reactions, but are differentially 
regulated and can act on different substrates. This diversity 
provides alternative pathways for the highly controlled process of 
phospholipid degradation and metabolism (Serhan et al., 1996). 
PLA2 hydrolyzes several types of phospholipids to liberate free 
fatty acids and Iysophospholipids, which may either exert direct 
effects or serve as substrates for the generation of other lipid 
messengers such as eicosanoids, lysophosphatidic acid, or platelet-
activating factor (Balsinde et al., 1996). Of particular interest is 
the release of free arachidonic acid (AA), which serves as the 
presursor for numerous bioactive eicosanoid products (Serhan et al., 
1996). Mammmalian cells have been shown to contain multiple 
structurally-diverse PLA2 enzymes (Dennis, 1994).. At least three 
different cellular PLA2S have been shown to play a role in the 
mobilization of AA from phospholipids. These include cytosolic 
group IV PLA2S (Lin et al. , 1993; Kramer et al., 1993; Qiu et al., 
1993), the secretory group II PLA2S (Murakami et aI., 1993; Barbour 
et al., 1993; Pfeilschifter, 1993), and a cytosolic calcium-




Receptor PC, etc --__ ... ~Arachidonic acid + 
PLA 2 LySo-PhOSPhOIiPld,,---..... PAF 
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FIGURE 1-1. Overview of Lipid Mediator Function. 
Each phospholipase is thought to be independently activated to 
generate specific lipid-derived second messengers. The relative 
abundance of each pathway's enzymes and precursors are cell-
specific. Modified from: Serhan, C.N. Haeggstrom, J.Z., and Leslie, 
C.C. FASEB J. 10; 1147-1158, 1996. 
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Cytosolic calcium-dependent PLA2 is a substrate for protein kinase 
C (PKC), cyclic-AMP-dependent kinase, and ERK mitogen-activated 
protein kinase (MAPK) in vitro (Wijkander and Sundler, 1992; Lin et 
a/., 1993; Nemenoff et a/., 1993; de Carvalho et a/., 1996). It is 
activated when phosphorylated by ERKs (Sa et a/., 1995; Clark et aI., 
1995). Potential regulatory mechanisms for other forms of PLA2 
have not been clearly defined. 
PI-specific PLC hydrolyzes inositol phospholipids to generate 
two second messengers, inositol 1,4,5-triphosphate (IP3) and 1,2-
diacylglycerol (DAG) (Exton, 1994). IP3 interacts with a receptor on 
the endoplasmic reticulum to release calcium from intracellular 
stores (Bornfeldt et a/., 1995). DAG is responsible for activating a 
large family of PKC Isoenzymes that catalyze protein 
phosphorylation (Nishizuka, 1992; Bruch, 1996). Multiple isoforms 
of PLC have been identified in a variety of mammalian tissues. The 
different isoenzymes are differentially regulated by receptor-
tyrosine kinases, non-receptor tyrosine kinases, G-proteins, and 
calcium (Cockcroft et a/., 1992; Sternweis and Smroka, 1992). 
Phospholipase D (PLD) and sphingomyelinase (SMase), the 
topics of this thesis project, will be discussed in detail below. 
5 
1-2. Protein Kinase C 
Protein kinase C (PKC) consists of a family of related isoforms 
of serine/threonine-specifi.c phospholipid-dependent kinases 
(Nishizuka, 1992; Blum et a/., 1994). PKCs are central elements in 
cellular signaling. Agonist-induced membrane phospholipid 
degradation is required for PKC activation (Blum et a/., 1994). This 
step allows information from extracellular signals to be 
transmitted across the membrane. Activation of PKCs are essential 
for long term cellular responses 
differentiation (Blum et al., 1994). 
such as proliferation and 
Since PKCs play regulatory 
functions in signal transduction (Nishizuka, 1986; Brook et a/., 1991; 
Iwashita and Kobayashi, 1992), gene expression (Bernstein et al., 
1991; Trejo and Brown, 1991), and cell proliferation and 
differentiation (Felipo et a/., 1990; Minana et al., 1991), these 
enzymes are considered important in tumorigenesis and are a 
potential target of new cancer therapies (Blum et a/., 1994). 
PKCs exist as a family of 11 isoforms that have related 
structures, but differ with respect. to tissue specificity, 
developmental expression, and subcellular distribution (Newton, 
1995). The isoenzymes have been grouped into three functional 
6 
classes based on their biochemical and structural properties and 
cofactor regulation (Newton, 1995; Nishizuka, 1995). The best-
described and first-discovered isoforms are the conventional PKCs 
(cPKCs), (I, BI, BII, and 'Y (Liscovitch and Cantley, 1994; Newton, 
1995). cPKCs require either phospholipids, calcium, and DAG (or 
tumor-promoting phorbol esters) for activity (Liscovitch and 
Cantley, 1994; Newton, 1995). The next well-characterized group is 
the novel PKCs, which include of 0, c, 11 (L), e, and Jl (Liscovitch and 
Cantley, 1994; Newton, 1995). This group does not require calcium 
for activity. The least understood izoenzymes are the atypical PKCs 
(aPKCs) which consist of ~ and A (I) (Liscovitch and Cantley, 1994; 
Newton, 1995). This group is not regulated by DAGs or phorbol 
esters (Liscovitch and Cantley, 1994; Newton, 1995). Each class of 
PKCs appears to play distinct roles in controlling major cellular 
fu nctio n s. 
1-3. Phospholipase D 
Phospholipase 0 (PLD), first described in carrot roots and 
cabbage leaves by Hanahan and Chaikoff (Heller, 1978), catalyzes the 
degradation of phosphatidylcholine to phosphatidic acid plus choline 
7 
in the presence of water. All early studies concerning the PLD 
reaction were performed in plants. Subsequent studies have shown 
that PLD is expressed in microorganisms, mammals and yeast. 
Phosphatidylcholine-preferring PLD can be detected in homogenates 
and membranes from various mammalian tissues including lung, 
liver, adipose tissue, endothelium and spermatozoa, with lung and 
brain being the richest sources (Heller, 1978; Bocckino et al., 1987; 
Tettenborn and Mueller, 1988; Martin, 1988; Anthes et al., 1991; 
Geny et al., 1993; Stuchfield and Cockcroft,. 1993). In plants and 
microorganisms, the enzyme is found to exist in both particulate and 
soluble forms (Heller, 1978). In mammalian cells, PLD activity is 
found to be associated primarily with particulate fractions (Heller, 
1978). However, one group was able to detect PLD activity in the 
cytosol of various bovine tissues including lung, brain, spleen, heart, 
kidney, thymus, and liver as well as in rat lung (Wang et al., 1991). 
The different forms of PLD catalyze the same general reaction 
(Heller, 1978; Liscovitch, 1989): 
Phosphatidyl-R' + R"-OH .. Phosphatidyl-R" + R'-OH 
8 
When R" = H, PLD catalyzes a hydrolysis reaction to produce 
phosphatidic acid. When R"-OH is an alcohol, PLD catalyzes a 
transphosphatidylation reaction to produce phosphatidylalcohol. A 
variety of alcohols can serve as substrates (Ella et a/., 1997). PLD 
is unique from other phospholipases with respect to its broad 
substrate specificity, as well as in its abil ity to catalyze the 
"transphosphatidylation" reaction (Heller, 1978; Kobayashi and 
Kanter, 1987). Both hydrolysis and transphosphatidylation occur via 
a common phosphatidyl-PLD complex formed by the nucleophilic 
attack by PLD at the phosphorus of the substrate (Heller, 1978; 
Kobayashi and Kanter, 1987). The alcohol binding site associated 
with the transphosphatidylation reaction appears to be largely 
conserved between plant, yeast, and mammalian PLDs (Morris et al., 
1996). 
1-4. Regulation of Phospholipase 0 
The activation ot PLD has been implicated as a crucial step in 
a broad spectrum of physiological processes and diseases, including 
metabolic regulation, inflammation, secretion, mitogenesis, 
oncogenesis, neural and cardiac stimulation, diabetes, and 
9 
senescence (Exton, 1994). Since PLD has been identified as a 
potentially important component of these processes, its modes of 
regulation are under intense investigation. 
In many cell types, PLD is activated in response to a diverse 
array of growth factors and mitogenic agonists (Morris et al., 1996). 
PLD has been shown to be activated by the same agonists that 
activate phosphatidylinositol- and phosphatidylcholine-utilizing 
PLCs (PIP2-PLC; PC-PLC) (Thompson, 1991). Reports have suggested 
that activation of PLD can occur through multiple mechanisms 
involving PKC, calcium ions, tyrosine kinases and/or GTP-binding 
proteins such as Ras (Cockcroft, 1992; Exton, 1994), ARFs (Brown, 
1993; Massenburg et al., 1994; Cockcroft et al., 1994), Rho A and B, 
Rae and Cdc42 (Bowman et al., 1993; Exton, 1994; Siddiqi et al., 
1995). 
There appear to be multiple isoforms of PLD. Studies in 
numerous mammalian tissues and cell lines have identified PLD 
activities that differ in their subcellular localization, pH optima, 
dependence on divalent cations, and susceptibility to inhibition by 
fatty acids (e.g. oleate) and detergents (Morris et al., 1996). These 
results suggest the existence of PLD isozymes that differ with 
1 0 
respect to activation mechanism, substrate specificity, and co-
factor requirements (Exton, 1994). Studies in Leydig cells have 
shown that PLD activated by phorbol 12-myristate 13-acetate (PMA) 
preferentially hydrolyzes ester-linked phosphatidylcholine, whereas 
PLD activated by a G-protein-coupled receptor does not discriminate 
between ether- and ester-linked phosphatidylcholine (Lauritzen and 
Hansen, 1995). In contrast, Huang ,and co-workers (1992) using 
MOCK cells, showed that PMA-activated PLO selectively hydrolyzes 
ether-linked phosphatidylcholine, while ARF- or ·Rho-regulated PLD 
preferentially hydrolyses ester-linked phosphatidylcholine. Even 
though most forms of PLO prefer phosphatidylcholine, it has been 
shown that the cytosolic form of PLD not only hydrolyzes 
phosphatidylcholine, but also phosphatidylethanolamine and 
phosphatidylinositol (Wang e tal., 1991). Phosphatidylserine and 
phosphatidylethanolamine are both utilized by a recently-described 
yeast PLD that is calcium-dependent and does not perform a 
phosphatidylation reaction (Mayr et al., 1996). 
The involvement of PKC in the activation of PLD has been 
demonstrated by several approaches.. Treatment of cells with 
phorbol 12-myristate 13-acetate (PMA), an activator of PKCs, can 
1 1 
activate PLD but not PLC. More recently, a role for specific PKC 
isozymes in the regulation of PLD was shown by studies in which 
P K C a or - B were overexpressed (Ohguchi et at., 1996). 
Overexpression of PKCBI enhances PMA-induced PLD activity in rat 
fibroblasts (Pai et al., 1991). Overexpression of PKCa in Swiss-3T3 
fibroblasts (Eldar et at., 1993) elevates basal and agonist-
stimulated PLD activity in intact cells as well as In vitro. In 
membranes isolated from CCL39 fibroblasts (Conricode et al., 1994), 
only PKCa and -8 are capable of activating PLD. These results 
suggest that activation of PLD may be selectively mediated by 
particular PKC isoforms. 
The exact mechanism by which PKC activates PLD is not fully 
understood. It is possible that PKC directly interacts with PLD in 
membranes, or that PKC interacts with other membrane-associated 
proteins that in turn activate PLD (Ohguchi et ai, 1996). Conricode 
an co-workers (1994) have shown that PMA activation of PLD 
involves PKC but does not require ATP-dependent phosphorylation in 
Chinese hamster lung fibroblasts. According to Singer and co-
workers (1996), PKC may regulate signaling events through direct 
molecular interaction with downstream effectors as well as through 
12 
its well-characterized catalytic modification of proteins by 
phosphorylation. 
In cell-free preparations from several tissues, PLD activity is 
enhanced by the addition of calcium. Calcium is also required for 
GTPyS-stimulated PLD activity in granulocyte homogenates (Anthes 
et al., 1991; Xie and Dubyak, 1991) and for ATP-induced 
phosphocholine formation in hepatocyte membranes (Irving and 
Exton, 1987). By contrast, in several preparations, including 
hepatocyte membranes, homogenates from endothelial cells 
(8occkino et al. , 1987; Martin, 1988), spermatozoal extracts (Domino 
et al., 1989), and some T-Iymphocytes, PLD activities do not require 
calcium. This suggests that calcium requirement for PLD may vary 
among cell types, that some forms of PLD may require calcium, 
and/or that calcium may be indirectly effecting PLD through some 
unknown mechanism. Mayr and co-workers (1996) have identified a 
strictly calcium-dependent PLD in Saccharomyces cerevisiae. This 
60kDa PLD preferentially hydrolyzes phosphatidylserine and 
phosphatidylethanolamine. Unlike previously-characterized plant, 
yeast, and mammalian PLDs, this calcium-dependent PLD is not 
affected by P1P2 and does not catalyze a transphosphatidylation 
13 
reaction in the presence of alcohol (Mayr et a/., 1996). It appears 
that this calcium-dependent PLD is a member of a novel family of 
PLDs. Since mammalian PLDs are usually assayed through use of the 
transphosphatidylation reaction, it is not yet clear whether a 
similar calcium-dependent enzyme is expressed in mammalian cells. 
A strong correlation between tyrosine phosphorylation and PLD 
activation was established in studies performed by Bourgoin and 
Grinstein (1992), in which treatment of permeabilized HL-60 cells 
with vanadyl hydroperoxide induced the accumulation of tyrosine-
phosphorylated proteins along with an increase in PLD activation. 
Uings and co-workers (1992) showed that three tyrosine kinase 
inhibitors blocked the activation of PLD induced by several agonists 
in neutrophils, whereas pervanadate increased tyrosine 
phosphorylation and PLD activity. These results suggest that PLD 
can be activated by an increase in tyrosine phosphorylation, thereby 
providing a role for tyrosine kinases in the regulation of PLD. 
Monomeric G proteins have been implicated as regulators of 
PLD in many mammalian cell types. Studies by Carnero and co-
workers (1994) have shown that, in NIH3T3 fibroblasts, mitogenic 
stimulation induced by Ras oncogenes is functionally linked to 
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activation of PC-PLD. Several other groups have identified ARF 
proteins as effective activators of PLD in HL-60 cells (Brown et al., 
1993; Cockcroft et al., 1994b). ARF is a 21 kOa guanine nucleotide-
binding protein that is responsible for enhancing the cholera toxin 
catalyzed ADP-ribosylation of the Gsa subunit that stimulates 
adenylate cyclase (Ding et aI, 1996). ARF has also been identified as 
an essential component of pathways for protein trafficking in cells. 
The small GTP-binding proteins of the Rho family, Rho A and -
Bt Rae, and Cdc42 , are implicated in signal transduction pathways 
that regulate both the actin cytoskeleton and mitogen-activated 
protein kinase (MAPK) cascade. The involvement of these proteins in 
the activation of PLD was demonstrated by Exton and colleagues, 
who showed that treatment of plasma membranes from rat liver 
with Rho-GOt reduced guanine nucleotide-stimulated PLD activity 
(Siddiqui et al., 1995). This activity could however be restored with 
the addition of purified RhoA protein. Subsequent studies revealed 
that a partially purified PLD preparation from porcine brain, as well 
as PLD activities in cytosol and membranes of HL-60 cells, could be 
activated by ARFs and by Rho A and ~B, Rae and Cdc42 (Morris et al., 
1996). Rho A has been shown to act synergistically with PKC to 
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stimulate activation of membrane-associated PLD activty in HL-60 
cells (Ohguchi et al., 1995; Ohguchi et al., 1996). Rho A and ARF can 
also exert a synergistic effect on PLD activation in several cell 
types, including HL-60 cells (Siddiqui et al., 1995; Morris et al., 
1996). Rho-specific GDP dissociation inhibitor can suppress 
synergistic PLD activation by GTPys and protein kinase C in HL-60 
membranes (Malcolm et al., 1994). These synergisms suggest that 
Rho A may be cooperatively regulating ARF- and protein kinase C-
induced PLD activity in HL-60' cells (Siddiqui et al. , 1995). Rac1 has 
been shown to play a major role in the activation of PLD by 
epidermal growth factor in Rat1 fibroblasts (Hess et al., 1997). 
Additional studies have shown that ARF- and Rho-responsive PLD 
activities are specifically stimulated when phosphatidylinositol 
4,5-bisphosphate is included in the substrate-containing 
phospholipid vesicles (Morris et al. , 1996). These results further 
suggest a role for this phospholipid as a cofactor or mediator of PLD 
activation. 
PLD can be negatively regulated by cellular cytosolic factors. 
According to Lukowski and co-workers (1996), a major increase in 
the total PLD activity was observed during an initial step of 
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purification of cytosolic PLD activators, suggesting the removal of 
an inhibitor. This group was later able to show that fodrin, a high 
molecular mass, cytoskeletal protein, was responsible for inhibiting 
PLD activity. A specific protein from bovine brain cytosol has been 
identified that potently inhibits PIP2-dependent PLD activity (Kim et 
al., 1996). This 30-kDa inhibitor specifically regulates PLD 
activity, but does not bind substrate vesicles containing PIP2. In 
addition, the suppression of PLD activity by the inhibitory protein 
can be reversed by the addition of ARF. These results provide 
further evidence for the involvement of cytosolic factors in 
negatively regulating PLD activity. The role of such factors In 
regulating PLD activity in intact cells is not clear. PLD activity can 
also be negatively regulated in intact cells via the heterotrimeric G-
protein, Gi (Ella et al., 1997). 
Despite the wealth of information concerning the biochemical 
properties of PLO, relatively little is known about its structural and 
molecular properties. An attempt to answer these issues led to ,the 
identification and characterization of a PC-specific PLD activity In 
plants (Wang et al., 1994). The cloning of this gene assisted in 
identification of the gene encoding a phosphatidylcholine-
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hydrolyzing PLD1 in the yeast, Saccharomyces cerevesiae (Ella et al., 
1996). This gene is localized to the site of the SP014 sporulation 
mutation (Waksman et al. , 1996), and encodes a PLD with 
transphosphatidylating catalytic activity (Ella et al., 1995; Ella e t 
al., 1996). Additional studies, using yeast PLD1 as a tool, led to the 
cloning and characterization of human PLD1 (Hammond et al., 1995). 
hPLD1 is membrane-associated and IS activated by 
phosphatidylinositol 4,5-bisphosphate and by ARF (Hammond et al., 
1995). A splice variant of this gene was recently characterized 
(Hammond ef al. , 1997). The characterization of each of the PLDs 
encoded by each of these genes will be essential for revealing 
structural features of PLDs and their mechanisms of regulation. 
1-5. Mechanism of Action of Phosphatidic Acid 
Phosphatidic acid (PA), product of the reaction catalyzed by 
PLD, may act as an intracellular second messenger in PLD-mediated 
signaling processes. The role of PA has been difficult to establish 
because this substrate is taken up poorly by cells, and can be 
metabolized on the outer surface of the cell. Nonetheless, PA is 
mitogenic for some mammalian cell types. In epithelial cells, PA 
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has been shown to increase release of calcium from intracellular 
stores and to stimulate synthesis of DNA (Moolenaar et aI., 1986). In 
3T3 fibroblasts, PA is highly mitogenic. This effect can. be seen 
following down-regulation of PKC, but is blocked by antibodies to 
ras proteins {Yu et al., 1988}. Additional studies in 8alb/c 3T3 
celis, using monoclonal antibodies to PA to quantify levels of PA, 
have also suggested that PA accumulation is important in 
mitogenesis (Fukami and Takenawa, 1992). All of these studies are 
complicated by potential metabolism of PA to active metabolites 
such as LPA. 
The molecular targets of PA remain poorly defined. PA can 
stimulate protein phosphorylation when added to cell extracts 
(80cckino et al., 1991; Meier, 1992). In human platelets, a PA-
activated protein kinase has been characterized (Khan et al., 1 994). 
PA has been shown to inhibit the GAP-mediated stimulation of the 
GTPase activity of Ras in vitro, as well as to stimulate activation of 
ARF-GAP proteins (Tsai et al., 1989). PA has also been shown to 
activate Ras-related p21 Rae-GAP activity (Ahmed et al., 1993). PA 
can bind to Raf-1 and enhance its activity (Ghosh et aI.., 1 996) . 
However, it has been difficult to address the significance of these 
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effects in intact cells. 
Lysophosphatidic acid (LPA), a product of PA metabolism and a 
contaminant of PA preparations, can act as an extracellular signal. 
LPA has been shown to be mitogenic in some cells (Moolenaar et a/., 
1986), and to activate PLD (Van der Bend et a/., 1992). There is 
increasing evidence that many cells possess a surface receptor for 
LPA (Thomson et a/., 1994). The function of this receptor is often 
blocked by pertussis toxin, an inhibitor of Gj-mediated signalling 
(Nagami et a/., 1995). Thus, many of the actions of LPA, such as PI 
hydrolysis, calcium elevation, AA release, inhibition of adenylate 
cyclase, chemoattraction, and PLD activation, can be attributed to 
receptor-activated G-protein-mediated mechanisms. LPA can also 
induce activation of ERK mitogen-activated protein kinases via Ras 
and Raf (Howe and Marshall, 1993; Hordijk et a/., 1994). This action 
can be mediated by activation of c-Src (Luttrell et al., 1996). LPA is 
a strong activator of Rho-dependent signal transduction pathways 
(Ahmed et al., 1993). While LPA can be released by platelets (Ohata 
et a/., 1996) and is a major growth factor in serum (Krebs et a/., 
1993), its potential roles as an autocrine or paracrine mediator have 
not been adequately explored. 
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1-6. Roles of Sphingolipids in Signal Transduction 
Based on the examples for glycerol-phospholipids, the roles of 
sphingolipids In signal transduction have been examined. 
Sphingolipids are complex lipids that serve a structural role in 
membranes. Sphingolipids consist of a long chain amino dialcohol 
base (sphingoid), an amide-linked fatty acyl group, and a polar or 
glycosidic head group (Hannun and Bell, 1993). The simplest 
sphingolipid, ceramide, serves as a precursor for more complex 
sphingolipids (Hannun and Bell, 1993). These include sphingomyelin, 
a major constituent of most membranes in eukaryotic cells, as well 
as neutral glycolipids and more complex acidic glycosphingolipids 
(Hannun and Bell, 1993). 
Sphingolipids have roles in the response to cell contact, as 
receptor components, as anchors for proteins, and as markers of 
tumor progression and cell differentiation (Hannun and 8ell, 1993). 
Sphingolipids also play a significant role in the regulation of cell 
viability (Hannun, 1996). In both Saccharomyces cerevisiae and 
mammalian cells, mutations in the first enzyme in de novo 
sphingolipid biosynthesis (serine-palmitoyl transferase) result In 
abolition of sphingolipid formation and loss of viability that is 
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reconstituted by replacement with sphingolipids (Hannun, 1996). 
A potential role for sphingolipids as signaling molecules 
became evident with the demonstration that sphingosine, an 
endogenous sphingolipid metabolite, reversibly inhibits PKC (Hannun 
et al., 1986). This observation prompted further investigations that 
led to the discovery of a sphingomyelin cycle of cell regulation and 
the potential role of ceramide as a second messenger/intracellular 
mediator (Hannun and Bell, 1989). 
1-7. Sphingomyelin Cycle 
The sphingomyelin cycle (Figure 1-2) was first characterized 
by Okazaki and co-workers in human HL-60 leukemic cells (Okazaki 
et al., 1989). When these cultured cells were labeled with choline 
and then stimulated with 1-a,25-dihydroxyvitamin 03, the levels of 
sphingomyelin changed substantially, indicating hydrolysis of 
cellular sphingomyelin to generate choline phosphate and ceramide 
(Okazaki et al., 1989). Other investigations were subsequently 
performed to examine the components of the sphingomyelin cycle, 
the hormone-activated enzymes regulating sphingomyelin 
hydrolysis, the role of sphingomyelin hydrolysis and the generated 
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Sphingomyelin 




FIG URE 1-2. The sphingomyelin cycle. 
Choline-
Phosphate 
Sphingomyelin is cleaved by sphingomyelinase to yield 
ceramide and choline phosphate. Sphingomyelin is regenerated from 
ceramide via the transfer of choline phosphate from 
phosphatidylcholine by action of phosphatidylcholine:ceramide 
choline phosphotransferase. Adapted from: Saba J. D., Obeid, L.M., and 
Hannun, Y.A. phUns. Trans. B. Soc. London B. BioI. Science. 351; 233-
240, 1996. 
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products in biological responses, and the extracellular inducers of 
/ 
\ 
sphingomyelin hydrolysis (Hannun and Bell, 1993). Evidence obtained 
thus far suggests that the sphingomyelin cycle is involved in the 
regulation of cell growth, differentiation, programmed cell death, 
and cell attachment (Hannun, 1994). 
The major components of the sphingomyelin cycle are: a} 
sphingomyelin, the substrate; b} sphingomyelinase, the enzyme that 
catalyzes the hydrolysis of sphingomyelin; c} ceramide and choline-
phosphate, products resulting from the hydrolysis of sphingomyelin; 
and d) the enzymatic pathway for the resynthesis of sphingomyelin 
(Kolesnick and Golde, 1994) (Figure 1-2). The enzymatic pathway 
for the resynthesis of sphingomyelin from ceramide occurs via the 
transfer of choline phosphate from phosphatidylcholine by action of 
phosph atidyl cho line :ce ra m ide ch 0 Ii ne phosph otransfe rase. 
Sphingomyelin is a naturally-occurring membrane lipid that is 
preferentially localized in the outer leaflet of the" plasma membrane 
of mammalian cells (Kolesnick, 1991). Sphingomyelin is composed 
of a long chain sphingoid-base backbone (predominantly 
sphingosine), a fatty acid, and a phosphocholine headgroup 
(Kolesnick, 1991; Saklatvaia, 1995). Sphingomyelin is hydrolyzed 
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via a PLC-like reaction catalyzed by the enzyme sphingomyelinase 
(SMase) (sphingomyelin phosphodiesterase) (Zhang and Kolesnick, 
1995) into phosphocholine and ceramide. The phosphocholine head 
group is released into the extracellular environment while ceramide 
is thought to diffuse within membranes, acting as an intracellular or 
membrane-localized messenger (Testi, 1996). 
Hydrolysis of sphingomyelin to ceramide has been described in 
a variety of cell lines in response to various stimuli, including 1-
(l,25-dihydroxyvitamin D3 (Okazaki et al., 1989; Okazaki et a I., 
1990), diacylglycerols (Testi, 1996), ionizing radiation (Haimovitz-
Friedman et al., 1994), progesterone (Strum et al., 1995), and 
chemotherapeutic agents (Strum et a/., 1994). Accumulation of 
ceramide derived from sphingomyelin hydrolysis can also result 
from binding of ligands to cell-surface receptors, including tumor 
necrosis factor receptor (Dressler et al., 1992; Yanaga and Watson, 
1992; Dbaibo et al., 1993; Kim et al., 1994), interleukin-1J3 receptor 
(Ballou et a/., 1992; Mathias et al., 1993), nerve growth factor 
receptor (Dobrowsky et al., 1994), FAS/APO-1 antigens (Cifone e t 
al., 1993), and CD28 (Testi, 1996). The mechanisms responsible for 




Sphingomyelinases (SMases), which are responsible for 
intracellular degradation of sphingomyelin to ceramide, are 
considered essential components of the sphingomyelin cycle. 
Several forms of SMase have been identified in variety of 
mammalian tissues and organs. Acid and neutral SMases were the 
first two enzymes identified. They are suggested to participate in 
signal-specific biological processes (Spence, 1994; Chatterjee, 
1994). The other forms of SMase include a cytosolic SMase (Okazaki 
et al., 1994), a zinc-stimulated SMase (Spence et al., 1989; Schissel 
et al., 1996), and an alkaline SMase (Duan et al., 1995; Nyberg et al., 
1996). 
Acid SMase is a lysosomal hydrolyase that is ubiquitously 
distributed in all tissues. Acid SMase acts optimally at pH of, 4.5-
5.5 in vitro (Spence, 1994). This enzyme does not require a cofactor 
for maximal activity and IS not affected by EDT A or Triton X-100 
(Kolesnick et al., 1991). Acid SMase activity is, however, inhibited 
by the thiol reagent dithiothreitol (OTT) and by some lipids and 
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detergents, such as fatty acids, sphingosine, and sodium dodecyl 
sulfate (SDS) (Maruyama and Arima, 1989). Kronke and co-workers 
(Wiegmann et al., 1992; Schutze et al., 1994) have suggested that 
acid SMase may be activated by some agonists. In this case, acid 
SMase is activated by DAG generated by a ligand-responsive 
phosphatitdylcholine-specific PLC (Wiegmann et al., 1992; Schutze 
et al., 1994). Mutation of acid SMase results in the two major 
subtypes of human Neimann-Pick Disease (NPD), an inherited 
disorder characterized by accumulation of sphingomyelin 
(Schuchman et al., 1991). Type A NPD is a rapidly progressing 
neurodegenerative disorder (Schuchman et al., 1991). Type S NPD 
causes manifestations limited to the reticuloendothelial system 
(Schuchman et al., 1991). Three human acid SMase cDNAs have been 
isolated and sequenced from fibroblast, placental, testis, hepatoma, 
and retinal cDNA libraries (Schuchman et al., 1991). Transient 
expression studies showed that type 1 transcript, the major species, 
encodes a catalytically active enzyme. Sphingolipid activator 
proteins (SAPs), or saposins, play a role in the hydrolysis of 
sphingomyelin via acid SMase (Kolesnick, 1991). Saposins (A, S, C, 
and D), are a group of homologous glycoproteins derived from a 
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single precursor, prosaposin, that enhance lysosomal hydrolase 
action (Kolesnick, 1991; Vaccaro et al., 1995). The action of these 
proteins was originally described as replacing detergent 
requirements in vitro (Kolesnick, 1991). Saposins A, B, and D have 
SMase-enhancing capabilities, while saposin C, also known as SAP-
2, enhances hydrolysis of sphingomyelin, glucosylceramide, and 
galactosylceramide by ~-glucosylceramidase (Qi et al., 1996). 
Neutral SMase is a membrane-bound enzyme that is thought to 
be co-localized with its substrate on the outer leaflet of the plasma 
membrane (Ghosh and Chatterjee,1987; Chatterjee, 1993). This 
enzyme requires divalent cations such as magnesium for activity 
(Ghosh and Chatterjee,1987; Kolesnick, 1991; Chatterjee, 1993). 
Neutral SMase has an optimal pH of 7.0-7.5. This enzyme can be 
activated in response to a number of extracellular stress-related 
stimuli. High levels of activity can be detected in brain and neural 
tissues (Chatterjee, 1993). Neutral SMase is believed to be most 
important in generating lipid messengers to regulate cellular 
functions including proliferation, differentiation, and apoptosis 
(Chatterjee, 1993; Hannun, 1994). A neutral, Mg2+-dependent SMase 
has also been identified in S. cerevisiae (Ella et al., 1997). 
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Okazaki and co-workers (1994) described a cytosolic SMase 
activated In HL-60 cells upon stimulation with 1-c:x , 25-
dihydrovitamin D3. This enzyme has optimal activity at neutral pH 
and does not require magnesium for activity. Cytosolic SMase is 
inhibited by copper, ferric iron, and zinc. Activity of this enzyme IS 
modestly enhanced by phosphatidic acid, phosphatidylserine, or 
phosphatidylinositol, but not by other major phospholipids (Okazaki 
et al., 1994). Cytosolic, magnesium-independent SMase is reportly 
activated during cell differentiation (Okazaki et al., 1994). 
Zinc-stimulated SMase, originally described by Spence and co-
workers (1989), was detected in fetal bovine serum and, in lower 
levels, in newborn human serum. Recent studies, have shown that 
zinc-SMase activity is secreted by human and murine macrophages, 
human skin fibroblasts, microglial cells, and several other cells in 
culture (Schissel et al., 1996). Zinc-SMase arises from the acid 
SMase gene independently of alternative splicing, suggesting a post-
translational modification (Schissel et al., 1996). This enzyme has 
optimal activity at a pH of 5.5 (Spence et al., 1989; Schissel et al., 
1996). Zinc-stimulated SMase is inhibited by AMP and EDTA 
(Schissel et al., 1996). The biological function of zinc-stimulated 
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SMase is unknown. However, it is hypothesized that this enzyme 
may play roles in physiological and pathophysiological processes 
involving extracellular sphingomyelin hydrolysis (Schissel et al. , 
1996) . 
Alkaline SMase is thought be a potential player in digestion of 
dietary sphingomyelin and in gallbladder diseases (Duan et al. , 1995; 
Nyberg et al. , 1996). Alkaline SMase has an optimal pH of 9.0 (Duan 
et al. , 1995; Nyberg et al. , 1996). This enzyme is enriched in brush-
border preparations of rat intestinal mucosa and is present in human 
duodenal content and meconium (Duan et al., 1995). It is also 
present in both human hepatic bile and gallbladder bile (Nyberg e t 
al., 1996). The activity of alkaline SMase is dependent on bile salts, 
but is not increased by Triton X-100. Calcium or magnesium does 
not change the activity of this enzyme in the presence of bile salts 
(Nyberg et al., 1996). 
1-9. Ceramide: An Intracellular Second Messenger 
Ceramide is a central molecule In sphingolipid structure and 
metabolism (Hannun, 1994). The activation of cellular 
sphingomyelinase generates ceramide along with phosphocholine. 
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These products are then recycled back to sphingomyelin, defining the 
sphingomyelin cycle (Hannun, 1994). 
Biological studies utilizing ceramide analogs have indicated 
that ceramide possesses biological activity and can directly affect 
cell growth and differentiation (Obeid and Hannun, 1995). Short-
chain C2-, C6- and C8-ceramides are widely used as cell-permeable 
analogs to examine effects of ceramide on intact cells (Hannun, 
1994). Their use was first demonstrated in HL-60 cells, in which 
exposure to C2-ceramide resulted in a' dose-dependent inhibition of 
cell proliferation that was accompanied by induction of the 
monocytic phenotype (Kim et al., 1991). Futhermore, ~-ceramide 
induced transcriptional down-regulation of the c-myc proto-
oncogene by blockade of transcriptional elongation (Kim et al., 
1991). These results suggest that ceramide-induced effects on cell 
proliferation may involve control of c-myc mRNA levels (Kim et al., 
1991). The effects of ceramide on cell differentiation have been 
extended to a number of other cell systems, such as T9 glioma cells 
and fibroblasts. Ceramide is also thought to play a role in the 
regulation of the transcription factor NFkB (Obaibo et al., 1993; 
Hannun and Obeid, 1995). Ceramide appears to activate NFkB poorly 
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when applied to intact cells, but effectively In permeabilized cells 
(Dbaibo et al., 1993; Hannun and Obeid, 1995). This raises the 
possibly that ceramide may be necessary but not sufficient for 
activation of NFkB (Obaibo et al., 1993; Hannun and Obeid, 1995). 
Early investigations of the biological activity of ceramide 
analogs were hindered by their potent cytotoxic effects. The 
cytotoxicity was stereoisomer-specific, implying that ceramide-
induced cytotoxicity was likely to be the result of an interaction 
between ceramide and a biological receptor, rather than the result 
of a nonspecific detergent-like effect on membrane integrity (Saba 
et al., 1996). In addition, molecules closely related to ceramide, 
such as dihydroceramide, lacked any significant cytotoxic activity 
(Pushkareva et al., 1995). This lead to the suggestion that ceramide 
may be a mediator of apoptotic cell death. 
Obeid and co-workers (1993) demonstrated the ability of C2-
ceramide to induce programmed cell death in U937 monoblastic 
leukemic cells. Ceramide potently induced internucleosomal DNA 
fragmentation. The effects were specific in that closely-related 
analogs of ceramide, such as DAG and dihydroceramide, were 
inactive (Jarvis et al., 1994). Apoptosis can also be induced in other 
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cell systems using Ca-ceramide (Jarvis et al., 1994). As is the case 
for other agonists that induce programmed cell death, the effects of 
ceramide can be inhibited by the addition of zinc, suggesting the 
involvement of calcium-dependent endonuclease (Pushkareva et al., 
1995). Other studies have suggested that ceramide may also 
participate in apoptosis induced by dexamethasome, crosslinking of 
antibodies, FAS ligand, or serum withdrawal (Pushkareva et al., 
1995). Obeid and co-workers (personal communication) have shown 
that transfection of a bacterial neutral SMase results in apoptosis 
of mammalian cells, while incubation of the cells with the 
exogenous bacterial SMase does not. These results suggest that 
despite the localization of sphingomyelin and/ or SMase to the outer 
leaflet of the plasma membrane, ceramide must be generated within 
cells to initiate apoptosis. 
A role for ceramide In cell-cycle regulation has also been 
proposed. In MOL T-4 leukemic cells, it was shown that serum 
withdrawal resulted in significant accumulation of ceramide 
(Jayadev et al., 1995). This was concurrent with the development of 
cell-cycle arrest in GO/G1 and initiation of apoptosis (Jayadev e t 
al., 1995). When MOLT-4 cells were treated with Cs-ceramide, a 
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specific arrest in the GO/G1 phase of the cell cycle was observed 
that was both dose- and time-dependent (Pushkareva et al., 1995). 
The retinoblastoma (Rb) gene product is centrally involved In 
regulation of the mammalian cell cycle. It inhibits cell-cycle 
progression, particularly in response to growth suppressors 
(Weinberg, 1991). The effects of ceramide on Rb phosphorylation 
were examined in MOL T-4 cells (Dbaibo et al., 1995). The addition of 
C s-ceramide, in concentrations similiar to those achieved during 
serum deprivation, resulted in a tim-e- and dose-dependent 
dephosphorylation of Rb. Subsequent studies performed in Rb-
deficient cells showed them to be resistent to ceramide-mediated 
g r 0 wt h i n h i bit ion. Cell lines that expressed either the tumor 
antigen SV40 or adenovirus EIA were also unresponsive to the 
growth-inhibitory effects of ceramide (Dbaibo et al., 1995). These 
results indicate that ceramide may participate In an Rb-dependent 
pathway leading to cell cycle arrest (Pushkareva et al., 1995). 
Ceramide levels were found to be significantly elevated In 
senescent cells, which are unable to undergo DNA synthesis or 
proliferative responses to serum stimulation (Venable et al., 1994). 
A role for ceramide in inducing senescence was demonstrated by its 
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ability to induce Rb dephosphorylation and cell cycle arrest in human 
diploid fibroblasts. Exogenously administered ceramide inhibited 
DAG generation and PLD activation in WI-38 human fibroblasts, thus 
mimicking the lack of PLD activation seen in senescent cells. 
Ceramide is also suggested to interact with the components of 
other signaling pathways. It was shown that C2-ceramide markedly 
enhanced the production of PGE2 in response to stimulation of human 
dermal fibroblasts with IL-1 (Ballou et al., 1992). Further studies 
reported that ceramide treatment also induced the expression of 
cyclooxygenase gene mRNA, and an increase in cyclooxygenase 
protein levels (Ballou et al., 1992). Cyclooxygenase is the rate-
limiting enzyme in the synthesis of PGE2 (Ballou et al., 1992). 
Ceramide has also been implicated in the regulation of PLD 
(Venable et a/., 1996). In HL-60 cells, ceramide has been shown to 
inhibit phorbol-ester-induced PLD activation. Ceramide did not 
interfere with translocation of protein kinase C to the membrane in 
response to phorbol ester. In a cell-free HL-60 system, ceramide 
interfered with PKC-mediated activation of PLD. 
Similiar to the effects observed in various mammalian cell 




markly inhibited by C2-ceramide (Fishbein et al., 1993). This effect 
is dose-dependent, stereospecific, and can be elicited by 
phytoceramide, the naturally-occuring yeast ceramide, but not by 
dihydroceramide (Fishbein et al., 1993). Sphingosine and 
phytosphingosine can also inhibit yeast growth (Ella et al., 1996). A 
ceramide-responsive phosphatase activity was identified in crude 
extracts of Saccharomyces cervisiae (Fishbein et al., 1993). While a 
SMase with activity at acid and neutral pH has been identified in 
yeast, it is not yet clear whether this enzyme hydrolyzes endogenous 
yeast sphingolipids. 
In summary, the available data indicate that ceramide serves 
as a lipid mediator in mammalian cells. However, the lack of 
information concerning the structure and regulation of neutral 
SMase has impeded progress in this area. 
1-10. Molecular Targets of Ceramide Action 
Ceramide is postulated to serve as a second messenger 
molecule. Several potential targets for ceramide have been 
identified. To exert its biological effects, ceramide may transduce 
intracellular signals by activating protein kinases (Mathias et aI., 
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1991; Liu et al., 1994) or protein phosphatases (Drobrowsky and 
Hannun, 1993). Kolesnick and co-workers (Kolesnick and Golde, 
1994) have described a ceramide-activated protein kinase (CAPK) in 
A431 human epidermal carcinoma and HL-60 cells. This enzyme 
appears to phosporylate the epidermal growth factor receptor and is 
activated by TNF-a and IL-1 (Kolesnick and Golde, 1994). Neither the 
specificity of ceramide activation of CAPK nor its role in 
intracellular signaling have been fully elucidated. 
PKC-~ is also a postulated target for ceramide action. This 
isozyme of PKC is not activated by DAG or phorbol esters. PKC-~ can 
be activated by ceramide in vitro and has been shown to play a role 
in ceramide- and TNF-a induced activation of the NFkB transcription 
factor (Lozano et al., 1994). 
Ceramide-activated protein phosphatase (CAPP) is another 
target for ceramide action. This phosphatase belongs to the class 
2A (PP2A) family of serine/threonine protein phosphatases (Hannun, 
1994). Studies using purified and reconstituted PP2A have shown 
that ceramide activates only heterotrimeric PP2A, and that the 
presence of the B-regulatory subunit of PP2A is essential for 
37 
imparting ceramide responsiveness (Dobrowsky and Hannun, 1993; 
Hannun, 1994). CAPP is activated by short and long chain ceramides, 
but not by sphingomyelin, sphingosine, or dihydroceramide 
(Dobrowsky and Hannun, 1993; Hannun, 1994). The specificities of 
lipid mediators for CAPP activation in vitro closely matches their 
specificities for various cellular activities of ceramide, including 
apoptosis (Dobrowsky and Hannun, 1993; Hannun, 1994). Okadaic 
acid, an inhibitor of serine/threonine protein phosphatases, inhibits 
CAPP in vitro over a concentration range of 1-10 nM (Dobrowsky and 
Hannun, 1993). Okadaic acid has also been shown to inhibit the 
effects of ceramide on c-myc downregulation as well as on growth 
inhibition (Dobrowsky and Hannun, 1993). These results provide 
evidence for the involvement of CAPP in ceramide-mediated 
responses. 
In summary, it appears that there may be several proteins 
serving as direct or indirect targets for the action of ceramide. To 
further establish the roles of PLD and SMase in signal transduction, 
the relationship of their activation to that of members of the 
mitogen-activated protein kinase (MAPK) family was explored ill 
this thesis project. Members of the MAPK family will be discussed 
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below. 
1-11. Historical Overview of Mitogen-Activated 
Protein Kinases 
MAPK was first identified by Sturgill and Ray (1986) in 3T3-LI 
adipocyte cells. This enzyme was referred to as microtubule-
associated protein kinase 2 kinase, or MAP-2 kinase, because it 
utilized MAP-2 as substrate in vitro. These researchers found that 
this kinase could phosphorylate and reactivate phosphatase-treated 
ribosomal 86 kinase (RSK) (Sturgill and Ray, 1987). RSK (pp 90rsk) is 
a 90 KDa S6 kinase that is activated by serine/threonine 
phosphorylation in response to mitogens and inactivated by protein 
phosphatases 1 and 2A (Sturgill and Wu, 1991). Subsequent 
experiments confirmed the previous observations with the use of 
insulin-activated MAP-2 kinase and inactive RSK from rat liver 
(Gregory et al., 1989), and epidermal growth factor stimulated MAP-
2 kinase and inactive RSK from Swiss 3T3 cells (Gregory et al., 
1989; Ahn and Krebs, 1990). These studies implicated MAP-2 kinase 
as a RSK kinase (Gregory et al., 1989; Ahn and Krebs, 1990). Later, 
two forms of MAP-2 kinase with molecular weights of 42 KDa and 
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44 KDa were purified from fibroblasts (Cooper, 1989). Due to the 
wide substrate specificity of these kinases, the original ~me of 
MAP-2 kinase was later changed to MAPK for "mitogen-activated 
protein kinase" (Boulton et al., 1990 Sturgill and Wu, 1991). 
However, when the 42- and 44-KDa kinases were sequenced, the gene 
products were referred to as ERKs (extracellular signal-regulated 
kinases) (Boulton et al., 1990; Sturgill and Wu, 1991). The two 
isoforms are referred to as ERK1 and ERK2 (Boulton et al., 1990; 
Sturgill and Wu, 1991). Activation of these kinases requires 
phosphorylation on threonine and tyrosine residues. However, 
removal of a phosphate either from the threonine (by phosphatase 
2A) or from the tyrosine (by CD45) results in inactivation of both 
ERK1 and ERK2 (Anderson et al., 1990; Boulton et al., 1991). 
Additional studies have confirmed the existence of several isoforms 
that comprise the MAPK superfamily. 
1-12. Mitogen-Activated Protein Kinase Family 
Mitogen-activated protein kinases (MAPKs) comprise a family 
of proline-directed serine/threonine protein kinases that have been 
implicated in the control of a broad spectrum of biological and 
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cellular events (Nishida and Gotoh, 1993; Slenis, 1993). MAPK 
members are considered components of the intracellular regulatory 
network that transduces extracellular cues to initiate intracellular 
responses (Cano and Mahadevan, 1995). These kinases are activated 
by separate signaling cascades conserved through evolution. Many 
components of the pathways are expressed in yeast, nematodes, 
Drosophila, and mammals (Cano and Mahadevan, 1995). Three major 
groups of MAPKs have been identified in mammalian cells. These are 
1) the extracellular signal-regulated protein kinases, ERK1 and 
ERK2, 2) the c-Jun NH2-terminal kinase or stress-activated protein 
kinase, JNK/SAPK, and 3) p38 (HOG1) kinase (Cano and Mahadevan, 
1995; Osborn and Chambers, 1996). Each MAPK group has distinct 
upstream activators and substrates (Cano and Mahadevan, 1995). 
MAPK pathways have been well characterized in yeast. 
Distinct MAPK cascades transduce signals that control pheromone 
responses, cell-wall biosynthesis, anQ osmosensitivity in yeast 
(Ammerer, 1994). Yeast MAPKs differ from mammalian MAPKs in 
that they regulate separate phenomena; i.e., they seem not to be 
activated in parallel in response to the same stimulus, and 
mutations in one cascade do not affect the phenomena regulated by 
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other stimuli (Ammerer, 19~4; Blumer and Johnson, 1994). In 
/ 
i 
contrast, the mammalian MAPK subtypes can be activated 
simultaneously via distinct parallel cascades in response to the 
same stimulus (Cano and Mahadevan, 1995). 
1-13. Extrace lIu lar Sig n ai-Related Protei n Ki nases 
ERK1 (p44mapk) and ERK2 (p42 mapk) are the predominant MAP 
kinase isoforms expressed in most mammalian cells (Boulton et al., 
1991). These kinases 'are structurally very similar and are widely 
expressed in various cells and tissues. ERK1 and ERK2 are activated 
by a number of extracellular stimuli, including growth factors (e.g., 
epidermal growth factor), cytokines, and some hormones that act 
through G-protein-coupled receptors (Schlessinger, 1993; Blenis, 
1993; Nishida and Gotoh, 1993; Marshall, 1994). Phorbol ester tumor 
promoters and other activators of protein kinase C can produce 
dramatic stimulation of both ERK1 and ERK2 (Pelech et al., 1992). 
ERKs are implicated in an array of cellular mitogenic events, 
including cell cycle progression and the control of meiosis. ERK1 
and ERK2 are inactive when dephosphorylated. Maximal activation is 
achieved by phosphorylation of both a threonine and a tyrosine 
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residue (Ahn et al., 1992; Zheng and Guan, 1993; Denton and Tavare, 
1995). This activation is brought about by the dual-specificity MAP 
kinase kinases, MEK1 and MEK2 (Ahn et al., 1992; Zheng and Guan, 
1993; Denton and Tavare, 1995). Downstream substrates regulated 
by ERKs include transcription factors (e.g., Elk-1 and ATF2), protein 
kinases (e.g., p90rsk), and several other targets (Davis, 1993). 
p54 MAPK and p44mpk are other isoforms of MAPK that have 
been isolated, but characterized to a lesser degree than ERK1 and 
ERK2. pS4 MAPK is found to be stimulated in the livers of 
cycloheximide-treated rats (Pelech and Sanghera, 1992). This 
isoform is approximately 50% homologous to rat ERK2 within its 
catalytic domain (Pelech and Sanghera, 1992). The p54 MAPK 
phosphorylates MAP2 preferentially, and is sensitive to inhibition by 
protein-tyrosine phosphatases as well as by the serine/threonine 
phosphatase 2A (Seger and Krebs, 1995). 
p44 mpk (MBP kinase) is a MAPK isoform that was originally 
shown to be activated near the onset of germinal vesical breakdown 
in maturing sea star oocytes (Pelech and Sanghera, 1992). Protein 
and nucleic acid sequencing studies have shown that p44mpk shares 
about 77% amino acid identity with ERK2 and ERK1 (Pelech and 
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Sanghera, 1992}. p44 mpk is activated In vitro by the src-family 
kinase p561ck (Pelech and Sanghera, 1992). Purified p44m pk can 
readily autophosphorylate on a serine residue with no detectable 
tyrosine phosphorylation (Sanghera et al., 1991). However, tyrosine 
phosphorylation occurs during oocyte maturation and is required for 
activation (Sang hera et al., 1991). 
1-14. c-JUN NH2-terminal Kinases 
JNKs, also termed stress-activated protein kinases (SAPKs), 
comprise a subfamily of MAPKs that bind to and phosphorylate the 
transcription factor c-Jun within its NH2-terminal domain (Hibi e t 
al., 1993). JNKs also phosphorylate other transcription factors, such 
as ATF2 and Elk-1, and thereby augment their transcriptional 
activity (Oerijard et al., 1994). These kinases have been 
characterized in a variety of mammalian· cells and tissues. Two 
major forms of JNK, JNK1 (46KOa) and JNK2 (55KDa), have been 
characterized in human cells (Hibi et al., 1993). The 46-KDa (JNK1) 
and 55-KOa (JNK2) kinases are similarly regulated. Both 
phosphorylate the amino-terminal domains of c-Jun, thereby 
potentiating its trans-activation function (Hibi et al., 1993). Both 
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forms require phosphorylation at threonine and tyrosine residues by 
MAP kinase kinase 4 (MKK4/SEK1), a dual specificity kinase (Sanchez 
et al., 1994; Davis, 1995; Derijard et al., 1995). JNKs are activated 
by a number of environmental stress-inducing stimuli; such as UV 
light (Derijard et al., 1994), gamma radiation (Chen et al., 1996), 
protein synthesis inhibitors (Kyriakis et al., 1994), ceramide 
(Westwick et al., 1995), DNA-damaging drugs (Yu et al., 1996b), 
chemopreventative drugs (Yu et al., 1996a), and inflammatory 
cytokines {Kyriakis et al., 1994}. In addition, JNK activity can also 
be induced by mitogenic signals, including growth factors, oncogenic 
Ras, CD40 ligation, and T-cell co-stimulation (Oerijard et al., 1994; 
Minden et al., 1994; Su et al., 1994; Sakata et al., 1995; Berberich e t 
a/., 1996; Chen et a/., 1996). In T-cells, JNKs can be synergistically 
activated by treatment with phorbol ester and calcium ionophore (Su 
et al., 1994). JNKs are implicated in both cell proliferation and 
apoptotic cell death. 
1-15. p3S MAP Kinases 
p38 MAPK is a homolog of the yeast HOG1 (high-osmolarity 
glycerol response-1) kinase (Derijard et al., 1995). p38 is activated 
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by dual phosphorylation on tyrosine and threonine residues by MKK3 
and MKK6 (Derijard et al., 1995; Han et al., 1996). Activation of p38 
MAPK is induced in response to lipopolysaccharide, hyperosmolarity 
interleukin-1, endotoxin, TNF, pro-inflammatory cytokines, heat 
shock, and DNA-damaging agents (Pandey et al., 1996). Activation of 
p38 MAPK can occur through c-Abl protein tyrosine kinase-
dependent and -independent mechanisms (Pandey et al., 1996). The 
substrate specificity of p38 MAPK differs from ERK or JNK kinases. 
p38 MAPK strongly phosphorylates transcription factor ATF2 (Post 
and Brown, 1996), but does not phosphorylate cPLA2, c-Myc, or c-Jun 
(Raingeaud et al., 1995). p38 MAPK appears to play a role in 
regulating inflammatory responses, including cytokine secretion and 
apoptosis (Xia et al., 1995). 
1.16. MAPK Phosphorylation Cascades 
Activations of MAPKs occur through a series of sequential 
protein-protein interactions and phosphorylation reactions (Seger 
and Krebs, 1995). Each MAPK cascade consists of a module of three 
kinases: a MAPK kinase kinase (MEKK or MKK), which phosphorylates 
and activates a dual-specificity MAPK kinase (MEK), which in turn 
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phosphorylates and activate a MAPK (Cobb and Goldsmith, 1995). 
Members of the G-protein Ras superfamily are involved in the 
activation of MAPK phosphorylation cascades (Marshall, 1995; Davis, 
1993). In the case of the ERK cascade, Ras exchanges GDP (guanosine 
diphosphate) for GTP (guanosine triphosphate) upon activation of a 
Ras-specific guanine-nucleotide exchange factor (Viciana and 
Downward, 1993; Vojtek and Cooper, 1995). In the GTP-bound state, 
Ras then physically associates with the N-terminal region of Raf, 
thereby recruiting this serine/threonine kinase to the plasma 
membrane, where it becomes activated by an unknown mechanism 
(McCormick, 1994). Raf in turn activates and phosphorylates MAPK 
kinase (MEK), which ultimately leads to the activation of MAPK (ERK) 
(Crews et al .. , 1993). Ras activation can also occur via protein-
tyrosine kinase receptors and G-protein-linked receptors. In this 
case, autophosphorylation of the receptor protein-tyrosine kinases, 
occunng as a consequence of ligand binding, provides docking sites 
for Grb2. Grb2 in turns interacts with the nucleotide exchange 
factor mSOS to activate Ras (Davis, 1993; Marshall, 1995) (Figure 
1-3). Activation of ERKs via G-protein-coupled receptors appears to 
involve c-Src and Shc (Torres and Ye, 1996). 
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Two member of the Rho family, Cdc42 and Rac, activate 
members of the JNK phosphorylation cascade in the same way that 
Ras activates Raf (Cano and Mahadevan, 1995; Vojtek and 
Cooper,1995; Coso et al., 1995). It is believed that the activation 
of MEKK by Cdc42 and Rac is mediated by PAK65 (Vojtek and Cooper, 
1995). PAK65 IS a Cdc42- and Rac-binding protein (Vojtek and 
Cooper, 1995). The direct binding of PAK65 to Cdc42 and Rac 
requires active GTP-bound Cdc42 or Rac, and stimulates the 
catalytic activity of MEKK, -which then phosphorylates and activates 
JNK kinase (SEK), which in turn phosphorylates and activates 
JNK/SAPK (Figure 1-3) (Vojtek and Cooper, 1995). 
The biological consequences and mechanism of activation of 
the mammalian p38 MAPKs are poorly understood and are under 
intense investigation. These kinases are postulated to be regulated 
similarly to the yeast HOG1 phosphorylation cascade. A MAP kinase 
kinase kinase (MAPKKK) referred to as apoptosis signal-regulating 
kinase 1 (ASK1) can activate MKK3/MAPKK6, which in turn activates 
the mammalian p38 MAPK and JNK (Ichijo et al., 1997) (Figure 1-3). 
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FIGURE 1-3. Mitogen-activated protein kinase signaling 
pathways. 
ERK, JNK, and p38 are MAP kinase family members that are 
activated through parallel kinase cascades. Interactions between 
components of the various pathways may occur. ERKs are activated 
by multiple G protein-linked receptors, growth factors, and phorbol 
esters. JNKs are activated by growth factors and stress-related 
responses. p38 MAPK is also regulated by stressful stimuli. 
Activation of the kinases ultimately leads to the induction of 
various transcription factors. 
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1-17. Goals and Significance of Thesis Project 
The overall goal of this thesis project was to investigate the 
roles of PLD and SMase in signal transduction in T-Iymphocytes. 
Previous and concurrent work in this laboratory used A7rS vascular 
smooth muscle cells and Rat-1 fibroblasts to study the potential 
role of agonist-induced PLD activation in ERK activation (Jones e t 
al., 1994; Knoepp et at., 1996). This laboratory also concurrently 
studied the expression and regulation of PLD in yeast Saccharomyces 
cerevisiae (Ella et aL, 1995). Results from these studies showed 
that the activation of PLD is not restricted to~ mitogenic signaling 
pathways, and that PLD activation is not sufficient for ERK 
activation. Nonetheless, phosphatidic acid has been proposed to 
regulate Raf (Ghosh et al., 1996), and can induce proliferation in 
some mammalian cell types (Flores et al., 1996). With regard to 
SMase, while ceramide appears to be involved in induction of 
apoptosis, products of sphingomyelin metabolism can also induce 
proliferation. Ceramide can activate ERKs in some cells (Olivera e t 
ai, 1992) and JNKs in others (Westwick et al., 1995). Thus, the role 
of PLD and SMase require further clarifications. 
It is now apparent that MAPKs can play very different roles in 
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different cell types. This is particulary apparent when fibroblasts 
and T-Iymphocytes are compared. ERK activation is required for 
mitogenesis in fibroblasts, but can be involved in cell death in T-
cells (Sansbury et al., submitted). JNK activation is required for 
proliferation of T-cells (Su et al., 1994), but is involved in 
apoptosis in fibroblasts. Since the regulation of T -lymphocyte 
proliferation and survival is of great importance with respect to 
human health, the roles of lipid mediators in regulating MAPK 
activities in T -cells is the focus of this thesis project. 
Two T-Iymphocyte cell lines, Jurkat and EL4, were used in this 
project. These are IL-2 independent human and murine cell lines, 
repectively. Jurkat has been extensively used as a model to study 
early events in T -lymphocyte activation and signal transduction. 
EL4 has been used for many years to study signal transduction 
leading to IL-2 expression. 
When this project was initiated, very little was known about 
the roles of PLD, SMase, and MAPKs, in T-cells. Products of the PLD 
and/or SMase reaction were proposed to participate in the activation 
of MAPKs, JNKs, or other protein kinases. Both ERKs and JNKs are 
activated in T-cells in response to ligation of the T ... cell receptor. 
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We therefore hypothesized that PLD and SMase are involved in MAPK 
activation in T-Iymphocytes. 
To address this hypothesis, Specific Aim I of this thesis 
project characterizes the effects of phorbol ester (PMA), and the 
antileukemic drug (Ara-C), on PLD and SMase activity in T -cells. 
Reports from other laboratories had shown that Ara-C activates 
SMase in some lymphoid cells (Strum et al., 1994). We show that 
treatment with phorbol ester stimulates acute activation of PLD in 
Jurkat, but does not affect SMase activity in either EL4 or Jurkat 
i 
cells. Ara-C does not affect PLD activity in either cell line, but 
increases SMase activity in EL4 and Jurkat T-cells. EL4 cells appear 
to Jack PMA-stimulated PLD activity. 
Specific Aim II of this thesis project explores the role of PLD 
and SMase in activation of ERKs and JNKs in T-cells. Activation of 
ERKs is detected in EL4 and Jurkat T-cells in response to treatment 
with phorbol esters. This activation does not however, appear to 
depend on PLD activation. Moreover, ERK activation is unaffected by 
treatment with Ara-C or ceramides. JNK activity is synergistically 
increased in EL4 and Jurkat following treatment with phorbol esters 
and calcium. Ara-C induces delayed activation of JNKs in both EL4 
52 
and Jurkat cells. 
Specific Aim III of this thesis project examines mechanisms 
underlying the activation of PLD and SMase. We conclude that PMA-
induced activation of PLD is probably not due to translocation of PLD 
or a direct interaction of PKCa with PLD 
Our findings from this project suggest that PLD and SMase are 
independently activated, and represent distinct signaling pathways 
in T-cells. The results of this study contribute to our understanding 
of T-cell activation and death. Moreover, the information obtained 
from this study provides additional knowledge regarding basic 
mechanisms involved in the activation of PLD, SMas9, ERKs, and JNKs 
in T- lymphocytes. 
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CHAPTER 2 
Effects of Phorbol Ester on Phospholipase D and 
Mitogen-Activated Protein Kinase Activities in T-
Lymphocyte Cell Lines 
54 
2-1. Introduction 
Activation of both phospholipase D (PLD) and ERK mitogen-
activated protein kinases are generally seen in response to phorbol 
ester in non-lymphoid cells. PLD hydrolyzes phosphatidylcholine to 
phosphatidic acid (PA), which can be converted to diglyceride and 
other lipid mediators (Liscovitch, 1991). ERKs, which are activated 
via a ras/Raf-dependent pathway, generally mediate mitogenic 
signals (Seger and Krebs, 1995). The c-Jun N-terminal kinases 
(JNKs) phosphorylate and activate c-Jun (Kyriakis et al. , 1994). 
JNKs, which are synergistically activated in T-cells by phorbol ester 
and calcium, have been linked to transcription of interleukin-2 (IL-
2) (Su et al., 1994). Both ERKs and JNKs are activated in T-cells 
following ligation of the T-cell receptor (TCR) (Su et al. , 1994). 
The mechanism of activation of PLD and its role in cellular 
signalling remain to be established. At least two forms of 
mammalian PLD exist (Hammond et al., 1995; Morris et al. , 1996). 
Some PLDs can be activated by the GTP-binding proteins ADP-
ribosylation factor (ARF) (Brown et al., 1993; Cockcroft et al., 1994; 
Massenburg et al., 1994; Hammond et al. , 1995) or rho (Malcolm et 
al. , 1994; Lambeth et al., 1995). Calcium-dependent activation of 
55 
PLD has also been reported (Olson et al., 1991; Gustavsson et al., 
1994). Primary T-Iymphocytes and most T-cell lines do not exhibit 
phorbol ester-activated PLD activity (Kinsky et al., 1989). However, 
in the Jurkat human leukemic cell line, PLD is activated by phorbol 
ester or TCR ligation (Stewart et al., 1991). Membrane PLD activity 
is present in mouse thymus, but not in primary murine or human T 
cells (Ella et al., 1994; Meier et al., 1994). These observations 
suggest that expression of PLD activity is regulated during T-cell 
differentiation and transformation. 
Activation of PLD has been proposed to play a role in mitogenic 
signalling (Kondo et al., 1992). PLD can be activated by growth 
factors in a pathway downstream of PI-PLC and PKC (Lee et al., 
1994). PA can be converted to diacylglycerol by PA 
phosphohydrolase, potentially supporting continued PKC activity. PA 
itself may act as a second messenger. A role for PA in Raf 
activation has been proposed (Ghosh et al., 1996). The role of PA in 
mitogenic responses is likely to vary between cell types (Jones e t 
al., 1994). The goal of this study was to examine the effects of 
phorbol ester on PLO, ERK, and JNK activities in the Jurkat and EL4 
T -lymphocyte cell lines. 
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2-2. Materials and Methods 
Cell Culture 
EL4 cell lines were originally provided by Dr. David Morris 
(Univ. of Washington); phorbol ester-responsive wild-type (WT) cells 
were used unless otherwise noted. Phorbol ester-resistant variant 
EL4 cells, in which PMA does not activate MAPKs, (Meier et al., 
1991) were used for some experiments. Jurkat and HL-60 cells 
were obtained from Drs. Sandra Slivka (Tanabe Research 
Laboratories) and Khapil Shalla (MUSC).· respectively. Cells were 
maintained in RPMI 1640 medium supplemented with 10% fetal 
bovine serum (UBI), non-essential amino acids, and 
pen icill i n/strepto myci n. 
Phospholipase 0 Assays 
For PLD assays In intact cells, approximately 1 x1 06 cells were 
incubated overnight In complete culture medium (1 ml) containing 10 
flCi/ml [3H]-palmitic acid (Dupont NEN). Triplicate or quadruplicate 
samples were used for each experimental condition. Cells were 
washed with ice-cold PBS and collected by low-speed centrifugation 
(Seckman). The cells were then incubated with and without 100 nM 
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PMA (LC Laboratories) in the presence and absence of 0.5% ethanol. 
Ethanol was added immediately prior to addition of PMA. At the 
conclusion of the incubation, cells were washed and ice-cold 
methanol/6 N HCL (SO:2 v/v, 0.3 ml) was added. This mixture was 
transferred to a glass tube, and 0.5 ml chloroform was then added. 
Phase separation was accomplished by the addition of 0.3 ml of 1 M 
NaC!. The lower organic phase was recovered and dried under 
nitrogen gas. Cellular lipids were extracted from the cells with 30 
JlI chloroform/methanol (90:10 v/v). Dipalmitoyl-PA (Sigma) and 
phosphatidylethanol (PEt) (Avanti Polar Lipids Corporation) were 
added to each sample as chromatography standards. Phospholipids 
were separated using thin-layer chromatography developed with a 
solvent mixture consisting of the upper phase of a mixture of ethyl 
acetate/2,2 ,4-tri methylpentane/acetic acid/wate r (90 :50 :20: 1 00, 
v/v in ml) to which 1 ml acetic acid was added. Areas containing PA 
and PEt, as well as the remainder of the lanes, were scraped and 
transferred to vials for liquid scintillation spectrometry (Beckman). 
The radioactivity contained in the PA and PEt bands is expressed as 
a percent of the total radioactivity recovered .from each lane. 
For PLD assays in broken cell preparations, cells were 
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incubated in the absence and presence of 100 nM PMA or 10 U/ml PLD 
from Streptomyces (Sigma). Cytosolic and membrane extracts were 
prepared as described for the ERK assay (see below). Membrane PLD 
activity was assessed in vitro using BODIPV-phosphatidylcholine 
( B PC; 2-decanoyl-1-(0-( 11-( 4 ,4-difl uo ro-5, 7 -d i methyl-4-bo ra -3a, 
4 a-d i az a,s - i ndacene - 3 - pr opi ony I) ami no) undecy I )s n-g I yeer 0 - 3-
phospho-choline; from Molecular Probes), as the fluorescent 
substrate. The reaction, containing 0.1 mM BPC, 150 mM NaCI, 200 
~M octylglucoside, 25 mM MES (pH 6.0), 10 mM HEPES (pH 7.5), %mM 
EGT A, 1 mM EDT A, 40 mM f3-glycerophosphate {pH 7 .5}, 1 mM DTT, and 
1% n-butanol in a final volume of 12.5 ~I, was initiated by addition 
of 10 J.l9 of membrane protein and incubated for 30 minutes at 30oC. 
Cabbage PLD, used as a positive control, was from Sigma. A 5-~1 
aliquot of the reaction mixture was applied to a plastic-backed 
silica gel G60 TLC plate without fluorescent indicator (Merck). The 
plate was developed using chloroform/methanol/water/acetic acid 
(45:45:1 0:1, v/v) Results were imaged using a Fluorlmager 
(Molecular Dynamics) or GDS 5000 gel documentation and analysis 
system (UVP Life Sciences). For some experiments, results were 
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FIGURE 2-5. Immunoblots for PLD in EL4, Jurkat, and HL-60 
cells. 
Equal amounts of membrane protein from EL4 and Jurkat cells 
were separated by SDS-PAGE and then immunoblotted with anti-PLD 
antibody. The migration positions of molecular size markers are 
shown o~ the right. 
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recognized a 120-kOa protein in Jurkat and HL-60. A doublet was 
visible is some experiments. The immunoreactive bands were 
predominantely localized to the membrane fraction (Figure 2-6). 
The mobility and localization of these bands were not altered by 
PMA treatment in Jurkat or HL-60. These bands were not detected in 
EL4. 
Effects of PMA on ERK Activity 
We have previously shown that ERKs are activated in response 
to PMA in WT, but not variant, EL4 cells (Meier et al., 1991). A 
similar response has been reported for Jurkat cells (Nel et al., 1990; 
Whitehurst et al., 1992; Marklund et al. , 1993; Su et al., 1994). The 
results shown in Figure 2-7 confirm that PMA stimulates ERK 
activity, measured as MBP kinase activity, in both WT EL4 and Jurkat 
cells. MBP kinase activity was increased by 270 + 52% in EL4, and, 
by 181 + 24% in Jurkat (mean + S.E.M., n. = 5 experiments for each 
cell line), in response to PMA. The lower fold activation in Jurkat 
cells likely reflects the higher basal activity of MBP kinases other 
than ERK in these cells; since MBP kinase activity in untreated cells 
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FIGURE 2·6. Immunoblot for PLD in membrane and cytosol 
from Jurkat cells. 
Jurkat cells were incubated with or without 100 nM PMA for 
the indicated times. Equal amounts of membrane and cytosolic 
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FIGURE 2-7. Effects of phorbol ester on ERK activity in 
Jurkat and EL4 cells. 
WT EL4 (panel A) and Jurkat (panel 8) cells were incubated for 
10 minutes in the absence and presence of 100 nM PMA and/or 2 JlM 
ionomycin. ERK activity was assessed in cytosolic extracts 
prepared from cells, using M8P as substrate. Each data point 
represents the mean + S.D. of values obtained from duplicate 
samples of cells. 
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the same experiment (n = 4). A combination of PMA and 2 J.lM 
ionomycin did not produce a further increase In ERK activity in 
either cell line. Phosphorylation of ERKs is accompanied by a shift 
in their electrophoretic mobility. A major immunoreactive band of 
approximately 42 kDa (ERK2) was detected in both EL4 and Jurkat 
cells (Figure 2-8). A 44 kDa band (ERK1) was also present, but is not 
easily visualized in this particular immunoblot. PMA treatment 
resulted in a shift in the electrophoretic mobilities of ERK1 and 
ERK2 in both EL4 and Jurkat cells. These data indicate that PMA can 
induce phosphorylation of ERKs in both EL4 and Jurkat cells. 
Effects of Bacterial PLD on EL4 Cells 
The data presented above suggest that generation of PA is not 
required for ERK activation in T-cells. Incubation of A7rS vascular 
smooth muscle cells with PLD from Streptomyces can increase 
membrane PLD activity and elevate PA levels (Kondo et al., 1992; 
Jones et al., 1994). While the chemical composition and localization 
of the PA generated has not been described, we have shown that 
bacterial PLD remains associated with cell membranes in A7rS cells 
(Jones et al., 1994). Phosphatidylbutanol (PBt) was generated by 
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FIGURE 2-8. Immunoblot for ERK in EL4 and Jurkat cells. 
WT EL4 and Jurkat cells were incubated in the absence or 
presence of 100 nM PMA for 10 minutes. Whole cell extracts were 
separated on SOS-PAGE and then subjected to immunoblotting for 
ERKs using pan-ERK antibody. Equal amounts of cellular protein 
were loaded in each lane. 
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membranes prepared from WT and variant EL4 cells incubated with 
bacterial PLD (Figure 2-9). The enhanced PLD activity is presumably 
due to association of bacterial PLD with cell membranes. The 
results shown here also confirm that neither WT nor variant EL4 
cells have PMA-stimulated PLD activity. 
The effects of bacterial PLD on intact EL4 cells were 
examined. Treatment of WT EL4 cells with bacterial PLD resulted in 
a much greater elevation of PA than seen under the same conditions 
for A7rS cells (Jones et al., 1994), suggesting that EL4 is less able 
than A7rS to metabolize PLD reaction products. However, while 
incubation with bacterial PLD resulted in profound increases in PEt 
and PA (Figure 2-10A), ERKs were not activated (Figure 2-108). 
" 
These data indicate that elevation of PA is not sufficient to induce 
activation of ERKs in EL4 cells. 
Effects of PMA on JNK Activity in EL4 and Jurkat Cells 
In T-cells, JNKs have been shown to be synergistically 
activated in response to co-stimulation with PMA and calcium 
ionophore (Su et al., 1994). The mechanism underlying this co-
stimulation has not been delineated. PMA alone has variable effects 
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Figure 2-9. PLD Activity in EL4 Membranes 
WT and variant EL4 cells were incubated with no additions 
("C"), with 100 nM PMA ("P"), or with 10 U/ml bacterial PLD ("0") 
for 10 minutes. PLO activity was assayed in membrane extracts 
prepared from the cells, using the in vitro fluorescent assay. The 
TLC separation of the reaction products is shown, with the 
migration positions of the substrate (BPC), PA, Iyso-BPC, and 
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Effects of bacterial PLD on ERK activity in 
In panel A, intact WT EL4 cells were incubated with 100 nM 
PMA or 10 U/ml bacterial PLD for 30 minutes in the presence of 0.5% 
ethanol. Phosphatidylethanol (PEt) and phosphatidic acid (PA) 
formation was assessed as described in the text. Each data point 
represents the mean + S.D. of values obtained from triplicate 
samples of cells. In panel B, WT EL4 cells were incubated with 100 
nM PMA or 10U/ml bacterial PLD for 10 minutes. ERK activity was 
assessed in cytosolic extracts prepared from cells, using MBP as 
substrate. Each data point represents the mean + S.D. of values 
obtained from duplicate samples of cells. 
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on JNK activity in different cell lines, with a slight activation 
previously reported for Jurkat cells (Su et al., 1994). As shown in 
Figure 2-11, PMA alone caused a slight activation of JNK in both 
Jurkat and EL4 cells. In both cell lines, JNK was synergistically 
activated in response to a combination of PMA and ionomycin. 
Treatment of Jurkat cells with exogenous bacterial PLD did not 
activate JNK (Figure 2-12). Thus, activation of PLD does not appear 
to be required for JNK activation. 
2.4. Discussion 
Phosphatidic acid, generated by the PLD reaction, has been 
proposed to play a role in mitogenic signalling in mammalian cells. 
, 
Possible mechanisms for this effect include a direct effect of PA on 
effector proteins (e.g., kinases or G-proteins), metabolism of PA to 
DG (a PKC activator), or metabolism of PA to LPA. LPA, a lipid 
mediator binding to a G-protein-coupled receptor, is mitogenic for 
some cell types (Moolenaar, 1995). 
Proteins involved in the ERK activation cascade are proposed 
targets for PA. While activation of ERKs is an early event in 
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FIGURE 2-11. Effects of PMA and ionomycin on JNK activity 
in EL4 and Jurkat cells. 
WT EL4 (upper panel) and Jurkat (lower panel) cells were 
incubated in the absence and presence of 100 nM PMA and/or 2 ~M 
ionomycin for 10 minutes. JNK activity was assessed in whole cell 
extracts, using a solid-phase assay with GST-jun as substrate. Each 
d~ta paint represents the mean ± S.D. of values obtained from 
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FIGURE 2-12. Effects of bacterial PLD on JNK activity in 
Jurkat. 
Single aliquots of Jurkat cells were incubated in the absence 
and presence of 100nM PMA, 2 J.1M ionomycin, and 10 U/ml bacterial 
PLD for 10 minutes. JNK activity was assessed in whole cell 
extracts, using a solid-phase assay with GST-jun as substrate. 
Similar results were obtained in two separate experiments. 
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proliferation (Jones et al., 1994; Lubinus et al., 1994). In mature T-
lymphocytes, ERKs are activated both by TCR ligation and by IL-2, 
but this activation is not required for proliferation (Alberola-lia e t 
al., 1995). Activation of JNK, which requires co-stimulation with 
PMA and calcium, is necessary for induction of IL-2 synthesis (Su et 
al., 1994). 
The results of our study confirm that PLD is expressed, and is 
activated in response to phorbol ester, in the Jurkat cell line. 
However, PLD activation and PLD activity were not observed in EL4 
cells. PLD activity was likewise not observed in human peripheral 
T-cells, murine splenic T-cells, and a variety of murine T-cell lines 
(Meier et al., 1994; Ella and Meier, unpublished data). These results 
are consistent with an earlier report that PLD activity is not 
present in human peripheral T-Iymphocytes (Kinsky et al., 1989). 
However, substantial PLD activity is present in membranes prepared 
from mouse thymus (Ella et al., 1994). Taken together, these results 
suggest that expression of PLD activity ceases at some point during 
T-cell differentiation. 
The number of isoforms of PLD expressed in mammalian cells 
is unknown, with a 120-kDa form the first to be characterized at the 
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molecular level (Hammond et al., 1995). A 120-kDa protein 
recognized by an antibody to PLD was expressed in Jurkat and HL-60, 
but not EL4. These results suggest that the absence of PLD activity 
in EL4 could be due to lack of expression of PLD. However, since the 
existence of at least one more mammalian isoform of PLD has been 
reported (Hammond et al., 1995, Hammond et al., 1997), it is 
possible that the other forms are expressed in T-cells, and that the 
120-kOa enzyme is not responsible for PMA-stimulated PLD activity 
in Jurkat and HL-60. Alternatively, since the factors regulating PLD 
activity have not been completely defined, the lack of PLD activity 
in T -cells could be due to an absence of positive regulation. 
The lack of correlation between PLD activity and ERK activity 
\ 
is reminiscent of results obtained previously for the A7rS vascular 
smooth muscle cell line (Jones et al., 1994). It remains possible, as 
proposed (Ghosh et al., 1996), that PA generated by PLD can 
contribute to Raf activation. However, since ERKs are activated to 
similiar extents in both EL4 and Jurkat, any contribution of PLD to 
ERK activation in Jurkat cells is apparently minor. 
We report here that PMA-stimulated JNK activity can be 
detected in either the absence or presence of PMA-stimulated PLD 
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activity. The ability of PMA to synergistically activate JNK In EL4 
cells, in which PLD is not activated, argues against a role for PLD in 
JNK activation. The observation that co-stimulation with PMA and 
ionomycin induces synergistic activation of JNK, but not PLD, 
suggests that JNKs do not playa role in PLD activation. It remains 
possible that activation of PLD in response to a physiologic agonist 
could contribute to other aspects of T-cell co-stimulation. For 
example, in some cell types, PA may serve as a source of DG to 
sustain PKC activation (Martinson et al., 1990). PA can also serve as 
a substrate for the PLA2-mediated production of Iyso-PA (LPA) 
(Moolenaar 1995). LPA is mitogenic for fibroblasts (Van Carven et 
al., 1989; Moolenaar, 1995), but has no effect on the proliferation of 
Jurkat cells (Tigyi et a/., 1994). Hence, the role of PLD in signal 
transduction may vary between cell types depending on the 
expression of proteins that generate, metabolize and/or respond to 
PA and LPA. 
In conclusion, these studies establish that expression of 
ptiorbol ester-sensitive PLD activity varies between different T-
lymphocyte cell lines. Activation of PLD is not required for the 
activations of either ERK or JNK seen in response to phorbol ester. 
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Efffects of Sphingomyelinase Reaction Products on 
Mitogen-Activated Protein Kinase Activity in T-
Lymphocyte Cell Lines 
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3-1. Introduction 
Sphingomyelinase (SMase) can be activated in response to 
extracellular 'signals, such as TNF-a,1 a,25-dihydroxyvitamin D3, and 
complement (Hannun, 1994). The SMase that is activated by 
extracellular signals in mammalian cells appears to be a neutral, 
Mg-dependent enzyme that is localized to the plasma membrane. The 
hydrolysis of sphingomyelin by SMase produces ceramide, a proposed 
lipid mediator (Kolesnick, 1991). Ceramide can effect the activity 
of protein kinases (Liu et al., 1994) and phosphatases (Dobrowsky 
and Hannun, 1992), interfere with protein-protein interactions 
(Kanety et al., 1996), and induce apoptosis (Obeid et al., 1993). For 
example, in quiescent Swiss 3T3 fibroblasts, ceramide has been 
shown to stimulate [3 H]thymidine incorporation and to act 
syngergistically with a wide variety of growth factors known to 
induce proliferation In these cells (Olivera et al., 1992). In 
contrast, the ability of ceramide to induce apoptosis has been 
demonstrated in both hemopoietic and nonhemopoietic cell lines, 
including fibroblasts and fibrosarcoma cell lines (Hannun and Obeid, 
1995). Ceramide is considered by many researchers to be an 
endogenous mediator of apoptosis that may modu late signal 
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transduction through AP-1 activation (Sawai et al., 1995; Hannun 
and Obeid, 1995). Ceramide has also been shown to inhibit phorbol-
ester-induced PLD activation as well as interfere with PKC-
mediated activation of PLD (Venable et al., 1996). The mechanism of 
activation of neutral SMase has not been established, but may 
involve activation of proteases (Pronk et al., 1996). 
Consistent with its proposed role in programmed cell death, 
ceramide has been shown to activate JNK kinases in some cell types 
(Kyriakis et al., 1994; Westwick et al., 1995; Welsh, 1996). In 
addition, ceramide has been reported to activate ERKs in HL-60 cells 
(Raines et al., 1993). ERKs are activated by growth factors and 
other agonists via a ras-dependent protein phosphorylation cascade 
involving Raf-1 and MEK (Seger and Krebs, 1995). JNKs can be 
activated in response to both cytotoxic agents (Kyriakis et al., 
1994; Chen et al., 1996) and growth factors (Minden et al., 1995). 
JNKs are activated downstream of the small GTP-binding protein rac 
(Minden et al., 1995; Coso et al., 1995) via a phosphorylation cascade 
involving PAK (8agrodia et al., 1995) and SEK (Moriguchi et al., 
1995). The tyrosine kinase PYK2 can activate JNK via ras/rac 














FIGURE 3-1. Proposed mechanism for SMase activation 
leading to JNK signaling. 
The antileukemic drug, Ara-C activates a neutral SMase in the 
plasma membrane resulting in hydrolysis of sphingomyelin (8M) to 
ceramide and phosphocholine. It is unknown whether ceramide 
indirectly activates JNK (e.g., via rac,cdc42), or directly activates 
kinases upstream of JNKs. JNK activation leads to activation of the 
transcription factors c-jun and ATF2. 
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may be important with respect to the signal transduced, since 
physiologic stimuli typically induce transient activation, while 
gamma radiation induces persistent activation (Chen et al., 1996). 
In T-Iymphocytes, JNKs are synergistically activated in 
response to a combination of phorbol ester and ionophore, or in 
response to ligation of the T-cell receptor (Su et al., 1994). These 
stimuli result in expression of interleukin-2 (IL-2) and stimulation 
of T-cell proliferation. Although JNK activation appears to be most 
important in the regulation of IL-2 expression, both ERKs and JNKs· 
" 
are activated by T-cell ligation in T-cells (Su et al., 1994). 
Recently, it was shown that T-cell receptor-mediated activation of 
both ERKs and JNKs is blocked in anergic T cells (Fields et al., 1996; 
Li et al., 1996). In non-lymphocytic cells, ERKs and JNKs are 
proposed to play opposing roles in the regulation of apoptosis, with 
JNK activation inducing cell death and ERK activation opposing it 
(Xia et al., 1995). However the existing literature suggests that JNK 
activation, but not ERK activation, is required for T-cell 
proliferation. 
The studies cited above suggested that ceramide may activate 
members of the MAPK family. We examined whether this was the 
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case in T-cells. Specifically, this study addresses whether 
ceramide is a second messenger inducing JNK or ERK activation in T-
cell lines. 
Several strategies have been used to elevate ceramide levels 
in mammalian cells. As discussed earlier, several cytokines can 
increase ceramide in intact cells (e.g., TNFa, IL-1). However, a 
response to these agonists is dependent on expression of the 
appropriate receptor in the cells of interest (Hannun and Obeid, 
1995). Long-chain ceramides, similar to those produced 
endogenously, are not cell-permeable and generally do not mimic the 
effects of agonists on intact cells. Short-chain ceramides have been 
widely used to mimic the actions of agonists that increase ceramide 
levels. C2- and C6-ceramide are cell-permeable, short-chain 
ceramides shown to elicit responses in a wide variety of cell types. 
Finally, exogenous bacterial SMase has been reported to elevate 
ceramide levels in intact cells and to induce signal transduction 
(Olivera at al., 1992). 
Ara-C has been reported to induce acute activation of SMase in 
HL-60 cells (Strum at al., 1994) and in other cell types (L. Daniels,-
personal communication). Ceramide can induce apoptosis in HL-60 
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via induction of AP-1, which contains c-Jun (Sawai et al .. , 1995). In 
fibroblasts, Ara-C activates JNKs via the tyrosine kinase c-Abl 
(Kharbanda et al., 1995). The role of such early signal transduction 
events in the cytotoxic response to Ara-C have not yet been 
establ ished. 
Ara-C, an anti-leukemic drug (Kharbanda et al., 1994; Strum e t 
al., 1994), is a nucleoside analog that is transported into the cell by 
a nucleoside transporter and is then sequentially phosphorylated to 
Ara-CTP: 
Ara-C .. Ara-CMP lit Ara-CDP .. Ara-CTP 
The cytotoxic metabolite of Ara-C, Ara-CTP, is incorporated into 
DNA, resulting in slowing of chain elongation and induction of strand 
breakage (Crisp et al., 1996). Ara-C causes DNA fragmentation and 
endonucleolytic DNA cleavage, which is a hallmark of apoptosis 
{Kufe et al., 1984}. Ara-CTP also acts as a competitive inhibitor of 
DNA polymerase. Accumulation of deoxyribonucleoside 
triphosphates (dNTPs) in response to Ara-C is thought to be 
responsible for disruption of DNA synthesis in susceptible leukemia 
cells (Crisp et al., 1996). Since Ara-C appeared to be a general 
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activator of SMase, and was known to be cytotoxic for In T-
lymphocytes, it was used as a model stimulus in our studies. 
3-2. Methods 
Cell Culture and Incubations 
Jurkat cells and wild-type EL4 cells (Gause et al. , 1993) were 
orig inally provided by Drs. S. Slivka (Tanabe Research Laboratories) 
and D. Morris (University of Washington), respectively. Cells were 
maintained in RPMI 1640 supplemented with 10% fetal bovine serum 
r 
(UBI), non-essential amino acids, and penicillin/streptomycin. Cells 
were incubated with the desired agents (100 nM PMA, {LC Services}, 
100 JlM Ara-C {Sigma}, 5 JlM ceramide {Sigma}, or 10 U/ml bacterial 
SMase, {Sigma}) in culture medium at 37oC, washed with ice-cold 
phosphate-buffered saline (PBS), resuspended in lysis buffer (20 mM 
HEPES {pH 7.S}, 80 mM B-glycerophosphate, 10 mM EGTA, 2 mM EDTA, 
2 mM DTT), sonicated, and sedimented by centrifugation (Seckman) 
at 100,000 x g for 20 minutes at 4oC. The supernatant (cytosol) and 
pellet (membranes) were used for ERK and SMase assays, 
respectively. Extracts prepared in whole-cell lysis buffer (20 mM 
Tris {pH 7.4}, 137 mM NaCI, 25 mM B-glycerophosphate, 2 mM sodium 
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pyrophosphate, 2 mM EDTA, 1 mM Na3V04, 1% Triton X-100, 100/0 
glycerol, 1 mM PMSF, 5 Jlg/ml aprotinin, 5 Jlg/ml leupeptin, 2 mM 
benzamidine, 0.5 mM DTT} were sedimented by centrifugation at 
100,000 x 9 for 30 minutes at 4oC. The supernatant was used for 
JNK assays. 
SMase Assay 
SMase activity was assayed in vitro using BOOIPY-
sph ingomyel i n (N-( 4,4-difluoro-5, 7 -di methyl-4-bo ra-3a ,4a-diaza-
s-indacene-3-pentanoyl}sphingosyl-phosphocholine, BSM, Molecular 
Probes, catalog #0-3522). BOOIPY is a trademark of Molecular 
Probes, Inc. The assay was performed as previously described for 
phospholip-ase D (refer to Chapter 2), except that magnesium was 
included. The reaction mixture (12.5 JlI) contained 10 J1,g membrane 
protein, 100 J..LM 8SM, 150 mM NaCI, 25 mM HEPES (pH 7.5), 5 mM 
EGTA, 1 mM EDTA, 40 mM B-glycerophosphate, 200 J..L M 
octylglucoside, and 3 mM MgCI2. The concentration of 3mM MgCI2 
was determined to be optimal for measurement of SMase activity in 
Jurkat membranes (Ella and Meier, unpublished observations). 88M 
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was solubilized prior to each assay by brief sonication in buffered 
solution (0.5 mM octylglucoside, 400 mM NaGI, 66 mM MES {pH 6.0}). 
Reactions were incubated for 60 minutes at 30oG. A 5-JlI aliquot 
was applied to silica gel G60 thin-layer chromatography plates 
• 
(Merck) and developed in chloroform/methanol/water/ acetic acid 
(45:45:10:2). Results were imaged and/or quantitated using a 
Fluorlmager (Molecular Dynamics) or scanning fluorescence 
densitometer (Helena Laboratories). Product formation was 
calculated as a percerit of total fluorescence to normalize for 
loading. Protein concentrations were determined using Coomassie 
reagent (Pierce). 
Protein Kinase Assays 
The methods used to assess ERK and JNK activity were 
described in Chapter 2. 
3-3. Results 
Characterization of SMase Activity 
A fluorescent assay was used to characterize SMase activity 
in cell membranes. This assay has been used to characterize a yeast 
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SMase (Ella et al., 1997). The substrate used, BSM, has a BODIPY 
fluorophore conjugated to the fatty acid at the 2-position of the 
sphingoid backbone. Similarly substituted sphingolipids can serve 
as substrates for neutral SMase, but not for lysosomal acidic SMase 
(Levade et al., 1991). In other words, acid SMases cannot hydrolyze 
sphingomyelins with a bulky substituent at the 2-position. 
As shown in Figure 3-2, membranes from Jurkat and EL4 cells 
convert 8SM to BODIPY-ceramide in the presence of magnesium. No 
SMase activity was present in cytosol. Similar results were 
obtained in the absence and presence of dithiothreitol, an inhibitor 
of acid SMase (Maruyama and Arima, 1989) (data not shown). The pH 
optimum was 7.5 for Jurkat membranes (data not shown). These 
data indicate that the in vitro assay detects a neutral SMase 
activity in a T-cell line. 
Effects of Ara-C and PMA on SMase Activity 
The efects of agonists on SMase activity in T-Iymphocytes had 
not been previously studied. The effects of Ara-C and PMA on 
membrane SMase activity were therefore examined. Ara-C 
consistently induced an increase in SMase activity. In Jurkat cells, 
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Sample: S-cer SSM EL4 EL4 Jurkat Jurkat SMase 




FIGURE 3-2. SMase activity in Jurkat and EL4 cells. 
SMase activity was assessed in membranes using an in vitro 
fluorescent assay with BSM as substrate in the absence and presence 
of 3mM MgCI2. The thin-layer chromatography plate was imaged by a 
Fluorlmager (printed w1th reverse contrast). BSM, BODIPY-ceramide 
(B-cer), and bacterial SMase incubated with BSM, were 
chromatographed as standards. MgCI2 did not alter the amount of B-
cer present in the absence of membranes or SMase (data not shown). 
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FIGURE 3-3. 
and EL4 cells. 
Effects of Ara-C on SMase activity in Jurkat 
SMase activity was measured in vitro. Panel A: Cells were 
incubated for the indicated times with 100 JlM Ara-C. Ceramide 
production is expressed as percent of total fluorescence. Panel B: 
Cells were incubated for 10 minutes with 100 JlM Ara-C or 100 nM 
PMA. Ceramide production, as percent of the value for untreated 
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FIGURE 3-4. Effects of Ara-C on SMase activity in Jurkat. 
Membrane SMase was measured in vitro using a fluorescent 
assay. Single aliquots of Jurkat cells were incubated for 10 minutes 
with 10 JlM Ara-C, 100 J.!M Ara-C, or 100 nM PMA. Ceramide 
production is expressed as percent of total fluorescence. Each data 
point represents the mean + S.D. of values obtained from duplicate 













Control PMA lonomycin Ara-C 
FIGURE 3-5. Effects of PMA and ionomycin on SMase 
activity in Jurkat. 
Membrane SMase activity was measured in vitro using a 
fluorescent assay. Single aliquots of Jurkat cells were incubated 
for 10 minutes with 100 nM PMA, 2 11M ionomycin, or 100 11M Ara-C. 
Ceramide production, as percent of the value for untreated control 
cells, is the mean + S.E.M. from three independent experiments. 
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labelled lipids was effective in resolving ceramide from other 
products (data not shown). Unfortunately, no increase in cerarnide 
levels was detected in these experiments. Since our major goal was 
to determine whether ceramide acts directly as a second messenger 
to induce MAPK activation, measurement of ceramide accumulation 
was not further pursued. The following sections describe more 
pharmacologic approaches to address the role of ceramide in T-cells. 
Effects of Ara-C and PMA on ERK and JNK Activities 
The effects of Ara-C, PMA, and other agents on ERK activity 
were examined. PMA activated ERKs in Jurkat in 10 minutes, while 
Ara-C had no effect (Figure 3-6A). C2-ceramide, a cell-permeable 
derivative (Gomez-Munoz et al., 1994), did not affect ERK activity. 
Similar results were obtained with EL4 (Figure 3-68), in which PMA 
activates ERKs (Chapter 2). 
JNKs were synergistically activated in Jurkat (Figure 3-7 A) 
and EL4 cells at 10 minutes by a combination of PMA and ionomycin, 
as previously reported (Su et al., 1994; Bradshaw et al., 1996). PMA 
alone slightly activated JNKs, while ionomycin, Ara-C, C2-ceramide 
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FIG·URE3 .. 6. Effects · of Ara;'C and C2-ceramide ' on ERK 
activity in Jurkat and E'L4 cells. 
In the same experiment, both cell types were incubated for 10 
minutes with 100 nM PMA, 100 JlM Ara-C, or 5 JlM C2-ceramide. 
Results from JurkatceUs are shown fn panel A, and from EL4 cell's 
in panel B.CytosolicERK activity is the mean + S.D. of values 
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FIGURE 3-7. . Effects of Ara-C and ceramides on JNK 
activity in Jurkat cells. 
In panel A, Jurkat cells were incubated for 10 niinuteswith 
100 nM PMA, 2 J.!M ionomycin,PMA +ionomycin, 100 JlM Ara-C, Ara-C 
+ PMA, 5 JlM C2-ceramide, C2-ceramide+ PMA, 5 JlM ceramide, or 
ceramide + PMA. JNK activity in whole cell extracts is expressed as 
the mean + S.D. from duplicate aliquots of cells. In panel B, single 
aliquots of Jurkat cells were incubated for 10 minutes with 100 nM 
PMA, PMA + lonomycin, 10 U/ml bacterial SMase, or 5 J-lM ceramide-
1-phosphate. Similiar results were obtained in two separate 
experiments. 
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minutes (Figure 3-7A) nor affected the response to PMA (Figure 3-
7 A). Ceramide-1-phosphate (5 JlM) and SMase from S. aureus (10 
U/ml) likewise did not activate JNK at 10 minutes (Figure 3-78). 
Higher doses of ceramides did not affect JNK activity (data not 
shown). 
Since cytotoxic agents can cause a slowly-induced and 
persistent stimulation of JNKs (Park et al., 1996), the effects of 
more prolonged incubations with Ara-C were examined. As shown in 
Figure 3-8A, JNK activation was observed when Jurkat cells were 
incubated for longer times with Ara-C. JNK activation was 
apparent by 90 minutes, and persisted for at least 120 minutes. 
Similar results were obtained in EL4, in which JNK activation was 
observed only after 120 minutes (Figure 3-88). 
Ara-C did not activate ERKs at 10-120 minutes In Jurkat 
(Figure 3-9) or EL4 (data not shown). 
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FIGURE 3-8. Effects of prolonged treatment with Ara-C on 
JNK activity in Jurkat and EL4 cells. 
Jurkat (panel A) and EL4 (panel 8) cells were incubated for the 
indicated times with 100 J.1M Ara-C. JNK activity is the mean + S.D 
of control (untreated cells) obtained from two independent 
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FIGURE 3-9. Effects of prolonged treatment with Ara-C on 
ERK activity in Jurkat cells. 
Jurkat cells were incubated with 100 JlM Ara-C for the 
indicated times or with 100 nM PMA for 10 minutes. Cytosolic ERK 
activity, measured as MBP kinase activity, is the mean + S.D of 
values obtained from duplicate aliquots of cells. 
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3-4. Discussion 
We have examined the potential role of SMase activation in 
regulating the activities of the ERK and JNK kinases in two T-cell 
lines. We show for the first time that Jurkat and EL4 cells express a 
membrane-localized neutral SMase. We also show that SMase 
activity is increased in membranes prepared from Ara-C-treated 
cells. One previous report indicated that the activated state of 
neutral SMase could be preserved in a broken-cell preparation 
(Strum et a/., 1994). ·With the exception of divalent cations, we and 
; 
others have not identified factors· that activate neutral SMase in 
membrane preparations. A role for proteases in SMase activation 
has been proposed on the basis of intact cell studies (Wright et a/., 
1996). Until suitable molecular pr'obes are developed for neutral 
SMase, it will not be possible to determine whether the enzyme is 
activated by covalent modification (e.g., phosphorylation), 
translocation, proteolysis, or via protein-protein interactions. 
Ceramide does not appear to activate the ERK cascade in Jurkat 
or EL4 cells. These results contrast with those observed in one 
study of HL-60 cells, in which ceramide induced ERK activation 
(Raines et al., 1993). However, in another study, ceramide inhibited 
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ERK activity in HL-60 cells (Westwick et al., 1995). Since ERKs can 
be activated by PKC activators in both Jurkat and EL4 cells (Chapter 
2), the lack of effect of Ara-C suggests that Ara-C does not 
significantly stimulate protein kinase C-mediated pathways in these 
T-cell lines. We were unable to detect any significant inhibitory 
effect of Ara-C on PMA-induced ERK or JNK activation in this study. 
JNKs were not activated at early time points after Ara-C 
addition, when SMase was activated, but were activated in response 
-to more prolonged treatment with Ara-C. This time course does not 
correlate with the acute (10-minute) activation of SMase by Ara-C 
in this and a previous study (Strum et al., 1994). Since SMase 
activity remains elevated for at least one hour, it is possible that 
accumulation of ceramide (or its metabolites) is a direct signal for 
JNK activation. However, we did not detect JNK activation following 
a 10-minute incubation with cell-permeable ceramides. Bacterial 
SMase induced acute JNK activation in hepatoma cells (Kyriakis et 
al., 1994) and HL-60 cells (Westwick et a/., 1995). Interpretation 
of these responses may be complicated by the· fact that bacterial 
SMase preparations can contain additional phospholipase activities 
(Ella and Meier, unpublished observations). Ceramide induces c-Jun 
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within one hour in HL-60 cells (Sawai et al., 1995), an effect that 
could be consistent with a delayed time course ofJNK activation. 
Taken together, these results suggest that ceramide can induce 
long-term effects on mammalian cells. Such effects, though of 
potential physiologic importance, make it more difficult to 
determine whether ceramide is truly a "second messenger." 
The role of SMase activation in the induction of apoptosis by 
Ara-C in cells of hematopoietic origin remains unclear. Although 
JNKs can be activated by "stressful" cytotoxic stimuli, their 
; 
positive involvement in T-cell proliferation (Su et al., 1994) 
suggests that their roles can vary between cell types. The balance 
of JNK and ERK activities can determine the final cellular response 
(Xia et al., 1995). In T-cell activation, both ERKs and JNKs are 
activated. In contrast, Ara-C activates only JNKs in Jurkat and EL4 
cells (this study) and in HL-60 cells (Westwick et al., 1995). The 
kinetics of the response may also be important. Lethal irradiation 
induces a prolonged activation of JNK that is not detected until after 
one hour (Su et aI., 1994). In fibroblasts, Ara-C activates JNKs only 
after two hours (Kharbanda et al., 1995). If activation of JNKs leads 
to apoptosis in the absence of ERK activation, perhaps it is 
11 0 
necessary that this response be initiated slowly (i.e., only in 
response to a persistent cytotoxic insult). Finally, apoptosis can be 
induced by withdrawal of positive signals for cell proliferation 
(Ishizaki et al. , 1995). Both ERKs and JNKs are activated by co-
stimulation of T-cells. Thus, activation of JNK in the absence of 
ERK activation may be an important aspect of the action of cytotoxic 
agents that activate SMase in T-cells. 
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CHAPTER 4 
Expression and Regulation of Phospholipase 0 




Phospholipase D (PLD), which catalyzes the hydrolysis of 
phosphatidylcholine (PC) to phosphatidic acid {PAl, is proposed to 
play an important role in signal transduction for many types of cells. 
PLD is activated in mammalian cells in response to growth factors, 
agonists that activate phosphatidylinositol-specific PLCs (PIP2-
PLCs), and phorbol esters (Exton, 1990). It is not clear how many 
forms of PLD exist. Although cytosolic forms have been described, 
the regulated forms appear to be membrane-bound. The mechanism 
l 
of activation of PLD may vary between isoforms. Several factors 
have been implicated in the regulation of PLD activity, including 
calcium, PKCs, protein-tyrosine kinases, and GTP-binding proteins 
", 
{Exton, 1994}. The GTP-binding proteins ARF and Rho activate some 
forms of PLD (Exton et al. , 1992; Cockcroft, 1992; Bowman et al. , 
1993; Liscovitch et al. , 1994; Siddiqui et al. , 1995; Brown ef al., 
1995). P1P2 acts as a cofactor for various forms of PLD, including 
ARF-dependent forms. PLDs may be synergistically regulated by 
PKC, ARF, and Rho (Ohguchi et al., 1996; Singer et al., 1996). 
PLD can be activated by PKC via mechanisms that mayor may 
not involve protein phosphorylation. Olson and co-workers (1991) 
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have reported that PMA-induced PLD activation is dependent on ATP 
in the neutrophil cell-free system~ Additional studies have shown 
that the effect of ATP on PKC-mediated PLD activation is mediated 
by phosphorylation in human neutrophils (Lopez et al., 1995). 
Membrane-bound PLD can be activated by PKC in a phosphorylation-
independent mechanism in Chinese hamster lung fibroblasts 
(Conricode et al., 1992). In these cells, the activation of PLD by PKC 
was observed in the absence of A TP, suggesting that PKC may 
activate PLD by an allosteric mechanism without A TP-dependent 
phosphorylation (Conricode et alt., 1992). In liver membranes, 
stimulation of PLD by PKC likewise does not require ATP (Lopez e t 
al., 1995). In HL-60 cells, Ohguchi and co-workers (1995) have 
shown that PKC-mediated PLD aotivation is suppressed by R031-
8425, a potent PKC inhibitor. These studies imply that a novel, 
phosphorylation-independent mechanism exists for PLD activation by 
PKC (Morris et a/., 1996). 
Recently, specific PKC isozymes have been implicated in the 
regulation of PLD. In HL-60 cells, PLD activity was found in 
partially-purified PKC fractions containing a, (31, 1311, and "{ isozymes 
'. 
(Ohguchi et al., 1996). PKCa and -~, but not -1, were able to activate 
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membrane-bound PLD (Ohguchi et al., 1996). Among these iSQzymes, 
PKCa was most effective in activating PLD. One report showed that 
Rho was required for activation of PLO by G-protein-coupled 
receptors, but not by PKC (Hess sf al., 1997). However, other 
investigators have found that PKC acts additively or synergistically 
with Rho (Singer e f al., 1996). Thus, the mechanism by which PKC 
activates PLD remains to be established. 
Our labor~tory has raised an antibody against a 12-amino acid 
portion of the yeast PLD sequence i that is conserved between plants 
and yeast. Ten amino acids (83%) of this sequence are conserved in 
human PLD1 a and 1 b, (Hammond ef al., 1997).. This antibody 
recognizes yeast and plant PLDs, as well as a 120-kOa band in a 
variety of mammalian cell lines. The 120-kOa band is not observed 
in EL4 cells, which lack significant PLD activity, but is observed in 
Jurkat cells, which express PLD activity (refer to Chapter 2). The 
120 kOa band is present mainly in membranes, and does not 
translocate from cytosol to membranes upon treatment of Jurkat 
cells with PMA. A 50 kDa band has also been observed ih both 
cytosol and' membranes from a variety of cell lines. This band may 
be an additional isoform of PLD. Additional bands of approximately 
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90- and 95- kDa are seen in some cells. 
hPLD1 can be activated in vitro by ARF, P1P2, and PKCa (Morris 
at af., 1996). Whether this is the major form of PLD regulated by 
agonists is not clear. The mechanism by which PKCa regulates the 
activity of hPLD1 has not been established. The subcellular 
localization of hPLD1 has not been reported. Moreover, as discussed 
in Chapter 1, there may be more than one form of agonist-activated 
PLD. This chapter describes studies designed to address some of 
these issues. I 
In our in vitro assays, agonist-stimulated PLD activity is 
detected in the absence of added GTP-binding proteins, guanine 
nucleotides, or ATP. There are at least two possible explanations 
for the observed retention of agonist stimulation. First, membrane 
PLD activity may be increased due to translocation of inactive PLD 
to the membrane, where it may be activated by binding to membrane 
constituents. Second, PLD already localized to the membrane may be 
activated by protein-protein (e.g., PLD-P~C) or protein-lipid (e.g., 
P L 0 - PIP 2) interactions that are preserved in the membrane 
preparation used for the in vitro assay. 
In this study, we explore the use of the anti-PLD antibody to 
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examine localization and regulation of agonist-activated PLDs in 
Jurkat T-cells and in PC-3 and LNCaP human prostate cancer cells. 
The potential for regulation of PLD by phosphorylation was 
examined. The potential interaction of PLDs with PKCa was also 
explored. 
4-2. Materials and Methods 
Cell Culture 
Jurkat cells were maintained as described in Chapter 2. PC-3 
f 
and LNCaP cells, originally obtained from the American Type Culture 
Collection, were maintained in F12K medium and RPMI medium, 
respectively, supplemented with 10% fetal calf serum (Atlanta 
>", 
Biologicals). Cells were incubated with 1 00 nM PMA (LC 
Laboratories) in culture medium at 37oC, washed with ice-cold PBS, 
resuspended in lysis buffer (20 mM HEPES, 80 mM 
B-glycerophosphate, 10 mM EGTA, 2 mM EDTA, 2 mM OTT, {pH 7.5}), 
sonicated, and sedimented by centrifugation at 100,000 x 9 for 30 
minutes at 4oC. The supernatant (cytosol) and pellet (membranes) 
were used for PLD assays .. 
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Phospholipase 0 Assays 
For PLD assays in intact cells, cells were incubated overnight 
in complete culture medium (1 ml) containing 10 J.1Ci [3H]-palmitic 
acid (Dupont NEN). Washed cells were incubated with and without 
100 nM PMA (LC Laboratories) in the presence and absence of 0.50/0 
ethanol. Triplicate or quadruplicate samp1es were used for each 
experimental condition. Cellular· lipids were extracted from the 
cells with chloroform/methanol and separated by thin layer 
chromatography as described in r Chapter 2. Spots containing 
phosphatidylethanol (PEt) and phosphatidic acid (PA) were collected 
for liquid scintillation spectrometry. Results are presented for each 
product as a percent of the total rC\dioactivity recovered. 
For PLD assays in broken cell preparations, cells were 
incubated in the absence and presence of 100 nM PMA. Cytosolic and 
membrane extracts were prepared as described in Chapter 2. 
Membrane PLD activity was assessed in vitro using a fluorescent 
substrate, BPC (Molecular Probes). Each reaction utilized 10 J.1g of 
membrane protein. The products were separated on silica gel G60 
TLC plates (Merck) and imaged using a Fluorlmager (Molecular 
Dynamics). Results were quantitated using a fluorescent scanning 
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densitometer (Helena Laboratories). Data are quantitated as a 
percent of the total fluorescent signal recovered from each sample. 
Immunoblotting 
For the immunoblotting experiments, whole cell extracts were 
prepared. Cells were incubated with and without 100 nM PMA and 
) 
incubated in lysis buffer (20 mM HEPES {pH 7.4}, 1% Triton X-100, 50 
mM NaGI, 1 mM EGTA, 5 mM B-glycerophosphate, 30 mM sodium 
pyrophosphate, 1 00 J.1g soc;lium orthovanadate, 1 mM 
phenylmethylsulfonyl fluoride, 10 1l9/ml aprotinin, and 10 J,lg I m I 
leupeptin. The Iysates were sedimented by centrifugation at 10,000 
x 9 for 10 minutes at 40C to remove debris. Supernatant proteins 
were separated by SOS-PAGE on 10 or 12.5% Laemmli gels and 
transferred to nitrocellulose membranes (Micron Separations, Inc). 
Primary antibodies to PLD (polyclonal) were prepared by immunizing 
a rabbit with the peptide CIIGSANINERS linked to keyhole limpet 
hemocyanin. The peptide represents amino acids 1107-1118 of 
yeast PLD1 (Ella et a/., 1996), corresponding (with two 
substitutions) to residues 907-918 of human PLD1 (Hammond et al. , 
1995). Anti-PKCa (monoclonal) was obtained from Transduction 
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Laboratories. After incubation with primary antibodies, 
immunoblots were developed using gold-labelled secondary 
antibodies with silver enhancement (Amersham). 
Immunoprecipitation 
Whole cell extracts were prepared as described above for 
immunoblotting. Antibodies to PKCa were' incubated with the 
extracts for 2.5 hours at 40C with mixing. Protein A~agarose (Santa 
Cruz Biotechnology) was then added; the incubation was continued 
for 1 hour. The agarose beads were collected by centrifigation, 
washed several times with buffer, and then boiled in Laemmli 
sample buffer. For denaturing conditions, anti-PKCa 
immunoprecipitations were carried out as described above, except 
that cells were extracted with boiling solution (1 % SDS/10 mM Tris 
Hel pH 7.4) and then sonicated. Proteins in the immunoprecipitate 
were subjected to immunoblotting as described above. 
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4-3. Results 
PLD in Jurkat cells 
In chapter 2, we showed that PLD is activated in response to 
PMA in Jurkat cells (Chapter 2). We examined the expression of PLD, 
using a newly-developed antibody against PLD. We were able to 
detect a 120-kDa immunoreactive protein in Jurkat cells (Chapter 
2). This band, which may correspond to human PLD1 and/or its 
splice variant (Hammond et al., 1997), was predominantly localized 
to the membrane fraction. We were also able to detect 90-95-kDa 
and 50-KDa bands in the cytosol and membrane fractions of Jurkat 
(data not shown). None of the bands were translocated or showed 
mobility shifts in response to treatment of cells with PMA. 
Additional experiments were performed to determine whether 
activation of PLD occurs as a result of protein phosphorylation. 
Membranes from control and PMA-treated cells were incubated in 
the absence and presence of alkaline phosphatase. As shown in 
Figure 4-1, PMA-induced PLD activity was substantially decreased 
in the presence of alkaline phosphatase. Similiar results were also 
seen for Ara-C-induced SMase activity (data not shown). As a 
positive control for phosphatase activity under the conditions used, 
121 
t I A 
s f alk lin h s h 
r 10 
1 2 
immunoblots were performed using anti-ERK antibody (data not 
shown). Reversal of the PMA-induced ERK mobility shift indicated 
that ERKs were dephosphorylated by alkaline phosphatase treatment 
under the conditions used. However, when the alkaline phosphatase 
preparation was boiled prior to addition to cell extracts (to denature 
the phosphatase), inhibition of PLD and SMase was still observed 
(Figure 4-1). This result suggests a non-specific inhibition by 
components of the alkaline phosphatase preparation. Therefore, 
these data do not establish wheth~r phosphorylation is involved in 
the activation of PLD and/or SMase in Jurkat cells. In view of the 
difficulties in interpreting the results of phosphatase treatment .in 
crude membrane preparation, we pr9ceeded to determine whether our 
anti-PLD antibody could be used to study regulation of PLD activity 
more directly. 
PLD in PC-3 and LNCaP Cells 
Jurkat cells express relatively low levels of PLD activity, 
making analysis of PLD regulation more difficult. Our laboratory has 
characterized several other cellular model systems in which PMA 
activates PLD activity (Jones et al., 1994; Knoepp et aI., 1996; Ella 
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at aI., 1997). For further studies of PLD regulation, wa chose to 
examine the effects of PMA on PLD activity in PC-3 and LNCaP cells 
(Qi et aI., submitted). These cells express high levels of PLD 
activity, as shown by the in vitro assay utilizing BPC as the 
fluorescent substrate in the presence of 1 % butanol (Figure 4-2). 
PLD activity was present in both PC-3 and LNCaP membranes, as 
detected by production of phosphatidylbutanol (Figure 4-2). PMA 
induced increases in PLD activity in both cell lines, as detected 
using intact cell assays (Qi et al., ?ubmitted). Activation of PLD by 
PMA could also be detected in membrane preparations (Qi et al., 
submitted), as was the case for Jurkat cells (Chapter 2). 
The study was continued by, using the anti-PLD antibody to 
identify putative PLDs. Bands migrating at 120, 95 and 50 KDa were 
consistently detected in both PC-3 (Figure 4-3) and LNCaP 
membranes (data not shown). The 120-KDa as well the 95-KDa band 
were found mainly in membrane fractions. The 95-KDa band could 
also be detected in cytosolic fractions within these cells. Neither 
the 120-KDa band nor the 95-KOa translocated from the cytosol to 
membrane upon PMA treatment. A 50-KDa band is present in cytosol 
and membranes from a variety of cell lines (Ella, ai, and Meier, 
124 
0: -... :r: 
m 
~ 
~ ~ • • L. ...-I ::s as w J a: 









FIGURE 4-2. PLD activity in mammalian cell membranes. 
Membranes prepared from EL4, Jurkat, Rat-1 HIR, PC-3 and 
A7r5 cells were incubated for 1 hour at 30 0 C with BPC in the 
presence of 1 % butanol. Reaction products were separated by thin 
layer chromatography and imaged using a Fluorlmager (printed with 
reverse contrast). 
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FIGURE 4-3. Immunoblot for PLD in LNCaP and PC-3 cells. 
In panel A, membranes from LNCaP and PC-3 cells were 
separated on SDS-PAGE and subjected to immunoblotting for PLD 
using anti-PLD antibody. Castor bean PLD was used as a positive 
control. Equal amounts of membrane protein were loaded in each 
lane. The position of major immunoreactive PLD bands are indicated 
by arrows. In panel B, PC-3 cells were incubated in the absence 
("C") and presence (UP") of 1 00 nM PMA for 10 minutes. Cytosol and 
membrane fractions were prepared and immunoblotted with anti-PLD 
antibody. The migration positions of molecular size markers are 
shown on the left. 
126 
unpublished observations}. This band was also seen in PC-3 and 
LNCaP (Figure 4-3). The SO-KDa band likewise did not translocate in 
response to PMA treatment. Some signal transduction proteins show 
apparent mobility shifts upon phosphorylation. However, none of the 
bands recognized by the anti-PLD antibody in cytosol or membranes 
shifted in response to treatment of PC-3 cells with PMA. 
In order to study effects of agonists on PLD phosphorylation or 
protein-protein interactions, an immunoprecipitating antibody is 
extremely useful. We tested the ability of our antibody to 
immunoprecipitate PLD by performing immunoprecipitations under 
standard and denaturing conditions. We tested for the presence of 
immunoprecipitated protein by immunoblotting with the same 
antibody. Unfortunately, we found that the anti-PLD antibody was 
unable to immunoprecipitate PLD (Figure 4-4). Although the 
sequence recognized by the antibody is near the c-terminus, its high 
degree of conservation suggests that it may lie within the catalytic 
site. Thus, the epitope may not be available for recognition by the 
antibody under non-denaturing conditions. The inability of the 
antibody to immunoprecipitate protein under denaturing conditions 















4-4. Immunoblots for PLD 
i m m uno p ree i p it ates. 
in PLD 
PLD was immunoprecipitated under non-denaturing conditions 
from whole-cell extracts prepared from PC-3 cells that had been 
incubated with (UP") or without ("C") 1 00 nM PMA for 10 minutes. 
Lanes labelled (Urn") were mock immunoprecipitations of untreated 
cells performed without PLD antibody. The immunoprecipitates, and 
the immunoprecipitation supernatants, were subjected to 
immunoblotting for PLD. Whole-cell extract from untreated cells 
were also immunoblotted with anti-PLD antibody (far left lane). The 
position of the major immunoreactive PLD bands, PKCa, and IgG are 
indicated by arrows. The positions of molecular size markers are 
indicated on the left. 
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An alternative approach to analyzing potential interactions 
between PLD and PKC interactions was tested. PKCex was 
i m m u no p reci p ita ted from whole-cell extracts. The 
immunoprecipitates were immunoblotted with the anti-PLD antibody 
to determine whether PLD associated with PKCex. In the experiment 
shown, PMA slightly enhanced levels of the 95-KDa species in PKC 
immunprecipitates (Figure 4-5). However, the amount of 
immunoreactive PLD proteins detected in anti-PKCex 
immunoprecipitates was not consistently increased by PMA 
treatment. While the IgG signal obscures detection of the 50-KDa 
band in this particular blot, no evidence for association of this 
protein with PKCa was obtained in additional experiments. 
PKCa immunoprecipitates were also analyzed for PLD activity, 
using the In vitro fluorescent assay. Although PLD activity could be 
detected in the immunoprecipitates, there was no significant 
increase in PLD activity in anti-PKCa immunoprecipitates from 
PMA-treated cells (Figure 4-6). Taken together, these results 
suggest that PMA does not enhance or promote the direct association 
of PKCa with PLD isoforms in PC-3 cells. 
129 
IP: PKCa 
18: PLD 18: PKCa 
WCE IP supernatant IP supernatant 




p120--' • - 4111- ___ ~-----
p95 --. 




FIGURE 4-5. Immunoblots to r PLD in PKCa 
i m m uno prec i p it ates. 
P K C ex was immunoprecipitated from whole-cell extracts 
prepared from PC-3 cells that had been incubated with ("P") or 
without ("C") 1 00 nM PMA for 10 minutes. Lanes labelled "m" were 
mock immunoprecipitations performed without PKCex antibody. The 
immunoprecipitates, and the immunoprecipitation supernatants, 
were subjected to immunoblotting for PLD and PKCex. Whole-cell 
extract from untreated cells were also immunoblotted with anti-
PLD antibody (far left lane). The position of the major 
immunoreactive PLD bands, PKCa, and IgG are indicated by arrows. 
The positions of molecular size markers are indicated on the left. 
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FIGURE 4-6. PLD activity in PKCa immunoprecipitates 
P K C (l was immunoprecipitated from whole-cell extracts 
prepared from PC-3 cells that had been incubated with or without 
100 nM PMA for 10 minutes. Mock immunoprecipitations were 
performed without PKCa antibody. The immunoprecipitates were 
resuspended in lysis buffer and PLD activity was assessed using the 
in vitro fluorescent assay. Data are expressed as the percent of 
total fluorescence present in phosphatidylbutanol (PSt) band. 
Similar results were obtained in two separate experiments. 
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4-4. Discussion 
Previous studies have shown that PLD activity is expressed in 
a number of mammalian cell systems. PLD is generally activated in 
response to phorbol esters that activate PKC. In this study, we have 
examined some of the potential mechanisms by which PKCs may 
activate PLD. 
We have attempted to determine whether protein 
phosphorylation is involved in the activation of PLD. We have 
characterized the expression of PLD using an anti-PLD antibody in 
Jurkat, PC-3 and LNCaP cells. Using immunoblotting techniques, we 
have found that each cell line expresses a 120-KDa PLD that may 
represent the cloned human PLD1 (Hammond et al., 1995). 
Confirmation that this protein is indeed hPLD1 will depend on the 
development of additional anti-PLD antibodies and/or use of RT -PCR 
to confirm expression of hPLD1 in PC-3 cells. The 95-kDa band may 
represent a form of PLD similiar in size to the plant enzyme (Wang 
et al., 1994). In addition, we have identified a 50-kDa band that may 
be an additional isoform of PLD. When PLD was partially purified 
from mouse lung membranes, a 50-kDa immunoreactive band eluted 
in fractions containing PLD activity (Ella et al., submitted). While it 
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is possible that this band represents a proteolytic product, this 
seems unlikely in view of the inclusion of multiple protease 
inhibitors in the tissue extracts. 
Our studies using alkaline phosphatase did not provide 
evidence for a role for dephosphorylation in PMA-induced PLD 
activity. Although alkaline phosphatase acts as a general protein 
phosphatase, it is possible that it does not dephosphorylate residues 
involved in the regulation of PLD activity. Use of other phosphatase 
preparations or incubation protocols may circumvent the problem of 
non-specific decreases in PLD activity. A more direct approach to 
examining PLD phosphorylation would be to use anti-PLD antibodies 
in immunoprecipitate PLD from [32P]-labeled cells. This approach 
must await development of immunoprecipitating antibodies. 
Alternatively, epitope-tagged PLDs could be immunoprecipitated 
from [32P]-labeled celts transfected with constructs encoding the 
tagged enzyme. Therefore, further approaches will be required to 
determine if phosphorylation, or any other covalent protein 
modifications, are involved in the activation of PLD. The 120 .. kDa 
and 50-kDa bands seen in Jurkat and PC-3 cells did not shift in 
electrophoretic mobility following PMA treatment. Although some 
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signal transduction proteins shift when phosphorylated, others do 
not. Therefore, these results further suggest, but do not prove, that 
protein phosphorylation may not be involved in the regulation of PLD. 
Until additional mammalian forms of PLD have been sequenced, it 
will not be possible to establish that all of the bands observed 
represent PLDs. 
This study has also examined the interaction of PLD with 
P KCa. Our observations provided no direct evidence for association 
of PKCa with PLD. Several factots may be responsible for these 
results. First, the anti-PKCa antibody used may not permit co-
precipitation of PKCa and PLD under the conditions used. Second, 
since it has been suggested in the literature that several isoforms 
of PLD exist (Hammond et al., 1995; Morris et a/., 1996), it is 
possible that the forms of PLD recognized by the antibody in PC-3 
cells do not require or interact with PKC for activation. 
Experiments are in progress in our laboratory to define the form(s) 
of PLD expressed in Jurkat and PC-3 cells. Third, it has not been 
established that PLD is selectively regulated by PKCa in this cell 
line. 
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While further studies will be required to elucidate the 
mechanism by which PKC regulates PLD in mammalian cells, our 
results are consistent with the general hypothesis that PLDs are 




General Discussion and Future Directions 
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5-1 Conclusions 
Several major conclusions can be drawn from the data 
presented in the previous chapters. First, It has been clearly 
established in this work that the expression of phorbol ester-
sensitive PLD activity varies between different T-Iymphocyte cell 
lines. Activation of PLD is not required for PKC-mediated ERK 
activation, and elevation of PA is not sufficient to activate ERKs. 
This was found to be the case in vascular smooth muscle cells 
(Jones et al. , 1994) and fibroblasts.> (Knoepp et al. , 1996), as well as 
in T-cell lines (Bradshaw et al. , 1996a). 
Second, it has been determined that activation of neutral 
SMase can be detected in EL4 and Jurkat T-cells in response to the 
antileukemic drug, Ara-C, using an in vitro fluorescent assay 
(Bradshaw et al. , 1996b). Ara-C does not result in activation of 
ERKs, and activates JNKs only after a lag of approximately 1 hour. 
Thus, it is possible that accumulation of ceramide as a result of 
SMase activation is a direct or indirect signal for JNK activation. 
Finally, these studies showed that translocation of PLD from 
cytosol to membranes is probably not involved in activation of PLD 
by PMA. As observed for both Jurkat and PC-3 cells, a 120 kDa 
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protein recognized by an anti-PLD antibody is constitutively 
localized to the membrane (Bradshaw et aI., 1996a; Qi et al., 
submitted). Our studies did not establish whether protein 
phosphorylation was required for PLD or SMase activation. A direct 
interaction between PLD and PKCa was not detected. 
This study is the first to examine the role of PLD and SMase in 
MAPK activation in T-Iymphocytes. Overall, our findings from this 
project suggest that PLD and SMase are independently activated, and 
thus represent distinct signaling pathways in T-cells. The results 
of this study contribute to our understanding of T-cell activation 
and death. Furthermore, the information obtained from this study 
provides additional knowledge regarding the basic mechanisms 
involved in the activation of PLO, SMase, ERKs, and JNKs. 
5-2. Implications and future directions 
An increasing number of studies have been initiated over the 
past few years to elucidate the involvement of PLD and SMase in 
cellular signaling processes. Studies of PLD regulation have 
suggested a role for PLD in intracellular protein trafficking and 
mitogenic signaling, and have established that members of the ARF 
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and Rho families of G-proteins can regulate PLDs (Morris et al. , 
1996). Studies of the sphingomyelin cycle have implicated SMase in 
inflammatory responses, differentiation, and apoptotic cell death 
(Hannun, 1994). Even with the large amount of accumulated 
knowledge concerning PLD and SMase, further studies are still 
necessary to understand the roles of these enzymes in biological 
processes. 
In T -cells, very little is known about the roles of PLD and 
SMase in signal transduction. ;- Therefore, this thesis project 
addressed the hypothesis that PLD and SMase are involved in T-cell 
signalling. The goals of this project were to: 1) examine the 
activation state of PLD using the tumor promoter, PMA, as a model 
compound for the study, 2) examine the activation state of SMase 
using an antileukemic drug, Ara-C, as a model compound for the 
study, 3) examine the role(s) of PLD and SMase in activations of 
ERKs and JNKs, and 4) examine mechanisms underlying the activation 
of PLD and SMase. 
EL4 (a murine thymoma cell line that is phorbol ester-
sensitive) and Jurkat (a human cell line derived from an acute T-cell 
leukemia) were primarily used as model systems for this study. 
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Jurkat cells are widely used as a model to examine the requirements 
of normal T-cell activation. These cell lines differ from normal T-
cells in that they do not require IL-2 for proliferation. They differ 
from each other in their requirements for activation of IL-2 gene 
expression. Jurkat cells do not respond to PMA alone nor PMA plus 
IL-1, but do produce IL-2 in response to PMA plus 
phytohemagglutinin or PMA plus calcium ionophore (Baldari et al., 
1991) EL4 cells respond to high concentrations of PMA alone, or to a 
suboptimal concentration of PMA in combination with either IL-1 or 
calcium ionophore, to produce IL-2. Jurkat cells thus differ from 
EL4 cells in that they lack IL-1 receptors and require calcium 
mobilization for IL-2 gene activation (Baldari et al. , 1991). It is 
thought that IL-2-independent growth in these cell lines results 
from constitutive activation of a transcription factor, such as NFAT. 
However, the early signal transduction events observed in response 
to cytokines or PMA/ionomycin appear analogous to those observed 
In mature T-cells. 
Our studies analyzing PLD and SMase activity have led to the 
finding that these enzymes are indeed regulated through different 
signaling systems in Jurkat and EL4. Our studies provide substantial 
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evidence that a great deal of variablity exists for phorbol ester-
induced PLD activity in different T-cell lines. This variability may 
be due to differences in expression of various PLD isoforms 
(Chapter 2). We have shown that phorbol ester-stimulated PLD 
activity is present in human Jurkat leukemic T-cells, but is absent 
in murine EL4 cells. Calcium, ARF, and/or GTPrs, which are known to 
be required for some forms of PLO, did not stimulate PLD activity in 
EL4 membranes. Several other T-cell lines tested, such as HT-2, 
also lacked phorbol ester-induced PlD activity_ Likewise, additional 
studies in our laboratory have shown that basal PLD activity is 
absent in human and murine peripheral T-cells (Ella et al., 1994). 
These data are similiar to those obtained by Kinsky and co-workers 
(1989), who showed that human peripheral blood lymphocytes lacked 
phorbol ester-stimulated PLD activity. On the other hand, work in 
our laboratory showed high levels of PLD in mouse thymus (Ella e t 
al., 1994). Since thymocytes comprise the bulk of thymic tissue, 
these results suggest that the expression of PLD activity is 
terminated at some paint during T-cell differentiation. 
Studies of the regulation of PLD have been complicated by the 
likelihood that multiple isoforms of PLD exist in both cytosol and 
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membranes of mammalian cells (Siddiqui et al., 1995). Studies have 
suggested at least two subclasses of PLD enzymes. These include 
ARF-activated and Rho-activated PLD enzymes, and those enzymes 
that are sensitive to fatty acids, such as oleate (Morris et al. , 1996). 
Thus far, genes encoding PC-specific PLD activity in plants, PC-
hydrolyzing PLD1 in yeast, and PIP2/ARF-activated hPLD1 in humans 
have been isolated and cloned (Wang et al., 1994; Morris et al., 1996; 
Hammond et al., .1997; Ella ef al. , 1996). Using this information, our 
laboratory raised an anti-PLD antibody corresponding to residues 
found in yeast PLD1 and hPLD1. We were able to detect several 
immunoreactive proteins of molecular weight 120, 95, and 50-kOain 
Jurkat and HL-60 cells (Chapter 2) using the anti-PLD antibody. 
These proteins could also be seen in the PC-3 and LNCaP prostate 
cancer cell lines, which express high levels of phorbol ester-induced 
PLD activity (Chapter 4). Our results from these studies lead to the 
following conclusions: 1) some cells lack PMA-activated PLD 
activity and 2) the lack of expression of PLD isoforms In T -cells 
may be responsible for absence of PLD activity. A better 
understanding of factors affecting the expression and regulation of 
PLDs is necessary for future advances in this area. 
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Some studies have shown PKC-dependent, but 
phosphorylation-independent, activation of PLDs. We were unable to 
show any direct evidence for the association of PKCa with PLDs 
(Chapter 4). Until additional forms of mammalian PLDs are isolated 
and sequenced, and additional antibodies developed, it will be 
difficult to establish the mechanisms responsible for PKC-mediated 
regulation of PLD activity. 
Our in vitro studies of SMase activity have established that 
this enzyme is regulated independently of PLD activation in T -cells. 
This project has revealed that a magnesium-dependent SMase is 
activated in EL4 and Jurkat T-cells in response to treatment with 
Ara-C, an anti-leukemic drug. The activity was found solely in 
membrane preparations and was maximal at neutral pH. SMase 
activity was not affected by treatment of cells with the PKC 
activator phorbol ester, or by treatment with calcium ionophore. 
These results confirm our hypothesis that PLD and SMase are 
independently activated. The mechanism of SMase activation has not 
been established. Progress in this area is limited by a lack of 
molecular information concerning the structure of neutral SMase. 
The roles of PLD and SMase activation in the MAPK 
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phosphorylation cascade have not been clearly defined in T-cells. 
The results discussed in Chapters 2 and 3 showed a lack of 
correlation between the activation of PLD or SMase and the 
activation of ERKs. It is possible that the PA generated by PLD 
contributes to, but is not required for, Rat activation. Our study 
shows that ceramide does not affect the ERK phosphorylation 
cascade in Jurkat and EL4 cells. These results are consistent with 
the general hypothesis that ceramide generation is anti-
proliferative. This hypothesis was further confirmed by the ability 
of C2-ceramide to partially induce DNA fragmentation, a hallmark of 
apoptosis, in EL4 cells (data not shown). We were however, unable 
to detect significant nuclear morphological changes associated with 
apoptosis in either Jurkat or EL4 in response to Ara-C or ceramides 
using microscopy techniques. 
In T-cells, JNKs are synergistically activated by PKC- and 
calcium-mediated pathways (Su ef al. , 1994). We were able to 
detect a similiar synergism in EL4 cells, which lack PLD activity, 
upon treatment with PMA and calcium. This suggested that PLD is 
not required for the activation of JNK. Likewise, the fact that 
calcium did not induce a synergistic activation of PLD also suggests 
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that JNK does not play a role in the activation of PLD. 
The involvement of SMase in JNK activation was, however, 
quite different from that of PLD. Even though JNK was not activated 
at early time points when SMase activation was initiated, we were 
able to detect JNK activity after prolonged treatment with Ara-C. 
Since SMase activity remains elevated for prolonged time in EL4 and 
Jurkat, these results are consistent with recent data suggesting 
that the accumulation of ceramide may induce cellular responses in 
non-lymphocytic cells. However, since addition of high 
concentrations of cell-permeable ceramides did not activate JNKs, 
the role of SMase activation in Ara-C-induced JNK activation remain 
unclear. Prolonged activation of JNKs may result in apoptosis, as 
suggested by work from other laboratories (Parks et al. , 1996; Testi, 
1996). However, it should be noted that the roles of ERKs and JNKs 
have not been completely elucidated in T -cells, where JNK 
activation is associated with proliferation and ERK activation is not 
required for proliferation" 
It is possible that PLD may be involved In proliferative 
responses in T-cells 1 while SMase is involved in anti-proliferative 
responses. Such observations could be beneficial not only in 
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developing new therapeutic approaches, but in developing a better 
understanding of apoptosis and growth suppression in T -cells In 
correlation with pathogenesis. Further studies will be needed to 
establish the linkage between activations of SMase and JNK In 
different cell types in order to elucidate the role{s) of SMase in cell 
death. Determination of the various mammalian isoforms of PLD, 
inhibitors of the enzymes, and interrelationship of the enzymes with 
various kinases will be necessary to provide targets for future drug 
development and clinical advancements. While similar studies of 
neutral SMase are only in their early stages, this enzyme is likely to 
emerge as an important clinical target in the future. 
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